Document:

QuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.004    
    

 
 

SECOND AMENDMENT    
    

        This SECOND AMENDMENT (this "Amendment") is made as of July 1, 2003 by and between BNP PARIBAS LEASING
CORPORATION, a Delaware corporation (as successor in interest to BNP Leasing Corporation) ("BNPLC"), and CHIRON CORPORATION, a Delaware corporation
("Chiron"). 

Recitals 

        A.    BNPLC
and Chiron executed, among other things, a Lease Agreement (as amended, the "Lease") a Purchase Agreement (as
amended, the "Purchase Agreement") dated as June 28, 1996 (but effective as of July 1, 1996), and a Ground Lease (as amended, the
"Ground Lease") dated as June 28, 1996 (but effective as of July 1, 1996), covering the Property located in Emeryville, Alameda County,
California. 

        B.    Chiron
has previously completed construction of the initial Construction Project described in Exhibit C of the Lease pursuant to the
terms of the Lease, and all Construction Advances have been previously made. 

        C.    Anticipating
Chiron's request for this amendment, BNP Paribas, San Francisco Branch, has on behalf of BNPLC requested the prior written approval of this Amendment by the
Participants. ("Participants" and other capitalized terms defined in the Lease and used but not otherwise defined in this
Amendment are intended to have the meanings assigned to them in the Lease.) All Participants have given such approval, as evidenced by their execution of the consents below. 

        NOW,
THEREFORE, in consideration of the mutual covenants provided herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged,
BNPLC and Chiron agree as follows: 

	2.
	Modifications
to Ground Lease.    The Ground Lease is hereby modified and amended as follows:

	a.
	The
expiration date of the Ground Lease Term (as defined in the Ground Lease) is extended from December 31, 2030 to December 31, 2037.

	b.
	The
definition of Rent Commencement Date in Section 1(n) is amended and restated as follows:

	(n)
	Rent
Commencement Date.    "Rent Commencement Date" means the earlier of (1) the first
Business Day of the first calendar month which is more than thirty days after the Designated Sale Date and which is after the date upon which Chiron and all subtenants or assignees of Chiron under the
Lease have relinquished possession of the Land and any part of the Improvements, or (2) the first Business Day in July, 2009.

	3.
	Modifications
to List of Defined Terms.    The List of Defined Terms attached to the Ground Lease, the Purchase Agreement and the Lease is hereby
modified and amended as follows:

	a.
	The definition of Designated Sale Date is amended and restated as follows: 

"Designated Sale Date" means the earlier of: 

	(1)
	any
Business Day designated as such in a notice given by BNPLC to Chiron after:

	(A)
	an
Event of Default or a breach by Chiron of any of the Purchase Documents (and the expiration of any applicable cure or notice periods which may be expressly provided in the Purchase
Documents), including any breach by Chiron of Paragraph 4 of the Purchase Agreement, which concerns Chiron's obligation to deposit Restricted Funds if certain conditions specified in that
Paragraph are not satisfied; or 

 

	(B)
	any
failure of Chiron for any reason whatsoever (other than because of a refusal by BNPLC to fund requested Construction Advances in breach of the Lease or when, but for the condition
specified in subparagraph of the Lease, such refusal would constitute a breach of the Lease), on the date which is 120 days before any Demand Deadline under the Guaranty, to have
(1) caused the initial Construction Project and any subsequent Construction Projects which are commenced prior to such date to have been completed in a good and workmanlike manner,
substantially in accordance with Applicable Laws, and otherwise in compliance with the provisions of (x) the Lease, (y) the Permitted Encumbrances and (z) the Development
Contracts, and (2) satisfied the conditions required to obtain with respect to then existing Improvements any final certificates of occupancy required for the use and occupancy thereof, a
certificate of compliance from the City of Emeryville and a certificate of completion from the Redevelopment Agency as contemplated by the Development Contracts;

	(2)
	any
Business Day designated as such in an irrevocable, unconditional notice given by Chiron to BNPLC; provided, the Business Day so designated by Chiron must be no earlier than thirty
days after the date of such notice, unless the notice is given as contemplated in subparagraph of the Lease when an Event of Default has occurred and is continuing, in which case the Business Date so
designated must be consistent with the requirements for an effective cure as specified in subparagraph of the Lease; or

	(3)
	the
first Business Day of July 2009. 

If
BNPLC sends a notice to Chiron pursuant to the preceding clause (1) properly designating a Designated Sale Date, and Chiron sends a notice to BNP pursuant to the preceding clause (2)
properly designating a different Designated Sale Date, the earlier of the two dates so designated shall be the "Designated Sale Date" hereunder regardless of which notice was first sent. 

	b.
	The
definition of Demand Deadline is amended and restated as follows: 

"Demand Deadline" means any date specified in the Guaranty as the date after which no new demand for payment may be made upon the Guarantor pursuant to
the Guaranty. As of the Effective Date, the Demand Deadline is December 31, 2007. 

	c.
	After
the date of this Amendment, no further Funding Advances shall be required or permitted. As of the date of this Amendment, Funding Advances in the amount of $173,330,000 have been
made. The definition of Funding Advances is amended and restated as follows: 

"Funding Advances" means (1) the Initial Funding Advance and (2) all future advances (which, together with Initial Funding Advance, are
expected to total but in no event exceed $173,330,000) made by BNPLC's Parent or any Participant to or on behalf of BNPLC to allow BNPLC to provide the Construction Allowance under the Lease. 

	d.
	The
definition of Guaranty is amended and restated as follows: 

"Guaranty" means the Guaranty dated June 30, 2003 given by Guarantor to BNPLC, guarantying the obligations of Chiron under the Lease, the
Purchase Agreement and the Ground Lease until December 31, 2007, as such Guaranty may be extended, supplemented, amended, restated or otherwise modified from time to time with the consent of
BNPLC. 

2

 

	e.
	The
definition of Guarantor is amended and restated as follows: 

"Guarantor" means Novartis, AG, the largest shareholder of Chiron and the successor of Ciba-Geigy, Ltd. through merger, and any
successor of Novartis, AG through merger. 

	f.
	The
definition of LIBOR Period election is amended and restated as follows: 

"LIBOR Period Election" for any Base Rent Period means a period of one month, three months, or six months, as designated by Chiron at least ten Business
Days prior to the commencement of such Base Rent Period by a notice given to BNPLC in the form of Exhibit attached to the Lease. (For purposes of the Lease a LIBOR Period
Election for any Base Rent Period shall also be considered the LIBOR Period Election in effect on (1) the Base Rent Commencement Date or Base Rent Date upon which such Base Rent Period begins
and (2) subsequent Base Rent Dates, if any, which occur before the date upon which such Base Rent Period ends.) Any Libor Period Election so designated by Chiron shall remain in effect for the
entire Base Rent Period specified in Chiron's notice to BNPLC (provided such Base Rent Period commences at least ten Business Days after BNPLC's receipt of the notice) and for all subsequent Base Rent
Periods until a new designation becomes effective in accordance with the provisions set forth in this definition. Notwithstanding the foregoing, however: (1) Chiron shall not be entitled to
designate a LIBOR Period Election that would cause a Base Rent Period to extend beyond the end of the scheduled Term; (2) changes in the LIBOR Period Election shall become effective only upon
the commencement of a new Base Rent Period; (3) for any Base Rent Period which will end on or after the first Business Day in October, 1999, the only LIBOR Period Election permitted shall be
one month if for any reason whatsoever Chiron shall not, before such period begins, have deposited all Restricted Funds required by Paragraph 4 of the Purchase Agreement or otherwise entered
into agreements with BNPLC which will excuse Chiron's obligation to deposit Restricted Funds as contemplated by that Paragraph; and (4) if Chiron fails to make a LIBOR Period Election
consistent with the foregoing requirements for any Base Rent Period, or if an Event of Default shall have occurred and be continuing on the third Business Day preceding the commencement of any Base
Rent Period, the LIBOR Period Election for such Base Rent Period shall be deemed to be one month. 

	g.
	The
Maximum Construction Allowance has been fully and completely advanced, and no further Construction Advances shall be required or permitted. The definition of Maximum Construction
Allowance is amended and restated as follows: 

"Maximum Construction Allowance" means an amount equal to $173,330,000, less the Initial Funding Advance. 

	h.
	The
definition of Qualified Right to Stock Sale Proceeds is amended and restated as follows: 

"Qualified Right to Stock Sale Proceeds" means an unencumbered assignable contractual right of Chiron, established by agreements in form and substance
satisfactory to each of BNPLC and the Participants in its sole and absolute discretion, to receive from Guarantor no less than $184,000,000 in cash proceeds from the issuance or sale of Chiron's stock
to Guarantor. It is understood that although agreements may exist between Chiron and Guarantor as of the Effective Date which would obligate Guarantor to purchase Chiron's stock for more than
$184,000,000, such agreements have not been reviewed or approved by BNPLC or Participants, and therefore prior to any such approval after the Effective Date, such existing agreements cannot establish
rights which would qualify under this definition. 

	i.
	The
definition of Residual Risk Percentage is amended and restated as follows: 

"Residual Risk Percentage" means 10%. 

3

 

	j.
	The
definition of Spread is amended and restated as follows: 

"Spread" means (1) on any date before construction of the initial Construction Project is complete, 0.25% (twenty-five basis points),
(2) on any date after construction of the initial Construction Project is complete but prior to July 1, 2003, 0.20% (twenty basis points), and (3) commencing on July 1,
2003 and thereafter, 0.40% (forty basis points). 

For
purposes of this definition, the initial Construction Project shall not be deemed complete until Chiron shall have (1) caused the initial Construction Project to have been completed in a
good and workmanlike manner, substantially in accordance with Applicable Laws, and otherwise in compliance with the provisions of (x) the Lease, (y) the Permitted Encumbrances and
(z) the Development Contracts, and (2) obtained with respect to then existing Improvements any final certificates of occupancy required for the use and occupancy thereof, a certificate
of compliance from the City of Emeryville and a certificate of completion from the Redevelopment Agency as contemplated by the Development Contracts. 

	k.
	The
Stipulated Loss Value is agreed to be $173,330,000.

	4.
	Modifications
to Lease.    The Lease is hereby modified and amended as follows:

	a.
	The
reference to "$195,000,000" on the first page is amended and restated to refer to "$173,330,000".

	b.
	The
first sentence of Paragraph 1 is amended and restated as follows: 

The
term of this Lease (the "Term") shall commence on and include the Effective Date, and end on July 1, 2009, unless sooner terminated as
expressly herein provided. 

	c.
	The
Term may be extended at the option of Chiron for two successive periods of five years each; provided, however, that prior to any such extension the following conditions must have
been satisfied: (A) at least 180 days prior to the commencement of any such extension, BNPLC and Chiron must have agreed in writing upon, and received the consent and approval of BNPLC's
Parent and all other Participants to (1) a corresponding extension not only to the date for the expiration of the Term specified above, but also to the date specified in clause (3) of
the definition of Designated Sale Date, the Demand Deadline (and a corresponding extension of the Guaranty), and (2) an adjustment to the Rent that Chiron will be required to pay for the
extension, it being expected that the Rent for the extension may be different than the Rent required for the original Term, and it being understood that the Rent for any extension must in all events
be satisfactory to BNPLC (and all Participants) and Chiron, in their sole and absolute discretion; (B) no Event of Default shall have occurred and be continuing at the time of Chiron's exercise
of its option to extend; (C) immediately prior to any such extension, the Lease, the Purchase Agreement, the Ground Lease and the Guaranty must remain in effect. With respect to the condition
that BNPLC (and all Participants) and Chiron must have agreed upon the Rent required for any extension of the Term, neither Chiron nor BNPLC (nor any Participant) is willing to submit itself to a risk
of liability or loss of rights hereunder for being judged unreasonable. Accordingly, each of Chiron and BNPLC (and each Participant) hereby disclaim any obligation express or implied to be reasonable
in negotiating the Rent for any such extension. Subject to the changes to the Rent payable during any extension of the Term as provided in this Paragraph, if Chiron exercises its option to extend the
Term as provided in this Paragraph, the Lease shall continue in full force and effect, and the leasehold estate granted thereunder to Chiron shall continue without interruption and without any loss of
priority over other interests in or claims against the Property that may be created or arise after the date hereof and before the extension. 

4

 

	d.
	Paragraph 4.(f)
is amended and restated as follows: 

(f)    Administrative
Fees.    Upon execution and delivery of this Lease by BNPLC, and again on each anniversary of the date hereof prior to the
Designated Sale Date, Chiron shall pay BNPLC an administrative fee (an "Administrative Fee") as provided in the letter agreement dated May 15,
2003 between BNPLC and Chiron. Each payment of an Administrative Fee shall represent Additional Rent for the first Construction Period or Base Rent Period during which it first becomes due. 

	e.
	Paragraph 10(a)
is amended and restated as follows: 

(a)    Liability
Insurance.    Throughout the Term Chiron shall maintain commercial general liability insurance against claims for bodily and personal
injury, death and property damage occurring in or upon or resulting from any occurrence in or upon the Property, in standard form and with an insurance company or companies reasonably acceptable to
BNPLC (and so long as the Guaranty specifies a Demand Deadline, then after the Demand Deadline BNPLC may reasonably require that such insurance be provided through insurance or reinsurance companies
rated by the A.M. Best Company of Oldwick, New Jersey as having a policyholder's rating of A- or better and a reported financial information rating of VI or better), such insurance
to afford immediate protection, to the limit of not less than $50,000,000 combined single limit for bodily and personal injury, death and property damage in respect of any one accident or occurrence,
with not more than $20,000,000 self-insured retention. Such commercial general liability insurance shall include blanket contractual liability coverage which insures contractual liability
under the indemnifications set forth in this Lease, but such coverage or the amount thereof shall in no way limit such indemnifications. The policy evidencing such insurance shall name as additional
insureds BNPLC and all Participants of which Chiron has been notified (including all of the Participants listed in Schedule). Chiron shall maintain with respect to each
policy or agreement evidencing such commercial general liability insurance such endorsements as may be reasonably required by BNPLC and shall at all times deliver and maintain with BNPLC written
confirmation (in form reasonably satisfactory to BNPLC) with respect to such insurance from the applicable insurer or its authorized agent, which confirmation must provide that insurance coverage will
not be canceled or reduced without at least thirty days notice to BNPLC. Not less than thirty days prior to the expiration date of each policy of insurance required of Chiron pursuant to this
subparagraph, Chiron shall deliver to BNPLC a certificate evidencing a paid renewal policy or policies. 

	f.
	Paragraph 10(b)
is amended and restated as follows: 

(b)    Property
Insurance.    Throughout the Term Chiron will keep all Improvements (including all alterations, additions and changes made to the
Improvements) which are located within the Property insured under an "all-risk" property insurance policy (not excluding from coverage perils normally included within the definitions of
extended coverage, vandalism, malicious mischief and, if the Property is in a flood zone, flood) in the amount no less than 100% of the replacement value (exclusive of land, foundation, footings,
excavations and grading) with endorsements for contingent liability from operation of building laws, increased cost of construction and demolition costs which may be necessary to comply with building
laws. Subject to the reasonable approval of BNPLC, Chiron will be responsible for determining the amount of property insurance to be maintained from time to time, but Chiron must maintain such
coverage on an agreed value basis to eliminate the effects of coinsurance. Such insurance must be issued by an insurance company or companies reasonably acceptable to BNPLC, and so long as the
Guaranty specifies a Demand Deadline, then after the Demand Deadline BNPLC may reasonably require that the insurance or reinsurance companies providing such 

5

 

insurance
be rated by the A.M. Best Company of Oldwick, New Jersey as having (1) a policyholder's rating of A- or better, (2) a reported financial information rating
of no less than VI, and (3) in the case of each such company, a reported financial information rating which indicates an adjusted policyholders' surplus equal to or greater than the
underwriting exposure that such company has under the insurance or reinsurance it is providing for the Property. Any deductible applicable to such insurance shall not exceed $20,000,000. Such
insurance shall cover not only the value of Chiron's interest in the Improvements, but also the interest of BNPLC, and such insurance shall include provisions that BNPLC must be notified at least
thirty days prior to any cancellation or reduction of insurance coverage. The policies under which Chiron maintains such insurance may be "blanket" policies covering not only the Property but other
properties occupied or owned by Chiron; however, all policies must provide that proceeds paid thereunder with respect to the Property will be payable to BNPLC and Chiron as their interests may appear,
it being understood between BNPLC and Chiron that such proceeds shall be paid to BNPLC as Escrowed Proceeds and will be applied in accordance with Paragraph 11 of this Lease. In the event any
of the Property is destroyed or damaged by fire, explosion, windstorm, hail or by any other casualty against which insurance shall have been required hereunder, (i) BNPLC may, but shall not be
obligated to, make proof of loss if not made promptly by Chiron after notice from BNPLC, (ii) each insurance company concerned is hereby authorized and directed to make payment for such loss
directly to BNPLC for application as required by Paragraph 11, and (iii) BNPLC may settle, adjust or compromise any and all claims for loss, damage or destruction under any policy or
policies of insurance (provided, that so long as no Event of Default shall have occurred and be continuing, BNPLC must obtain Chiron's consent to any such settlement, which consent will not be
unreasonably withheld). If any casualty shall result in damage to or loss or destruction of the Property, Chiron shall give immediate notice thereof to BNPLC and Paragraph 11 shall apply. 

	g.
	Paragraph 13(a)(iv) is
amended and restated as follows: 

(iv)    no
more than 33% of the space in any completed Improvements shall be subleased without BNPLC's prior consent to any Person that is neither (A) an Affiliate of Chiron nor
(B) the operator of a business in the subleased space that is related to the operation of Chiron's own business. 

	h.
	The
notice address of each of the parties referenced in Paragraph 24(a)(iii) shall be as follows: 

Address
of BNPLC: 

BNP
Paribas Leasing Corporation

12201 Merit Drive, Suite 860

Dallas, Texas 75251

Attention: Lloyd G. Cox

Telecopy: (972) 788-9140 

With
a copy to: 

BNP
Paribas

One Front Street, 23rd Floor

San Francisco, California 94111

Attention: Katherine Wolfe

Telecopy: (415) 296-8954 

6

 

And
with a copy to: 

Clint
Shouse

Thompson & Knight, LLP

1700 Pacific Avenue

Suite 3300

Dallas, Texas 75201

Telecopy: (214) 969-1751 

Address
of Chiron: 

Chiron
Corporation

Attn: Corporate Secretary

4560 Horton Street

Emeryville, CA 94608-2916

Telecopy: (510) 654-5360 

With
a copy to: 

Chiron
Corporation

Attn: Treasurer

4560 Horton Street

Emeryville, CA 94608-2916

Telecopy: (510) 601-3343 

And
with a copy to: 

Paul,
Hastings, Janofsky & Walker LLP

12390 El Camino Real

San Diego, CA 92130

Attention: Scott Biel

Telecopy: (858) 720-2555 

	5.
	Modifications
to Purchase Agreement.    The Purchase Agreement is hereby modified and amended as follows:

	a.
	The
reference to "$195,000,000" on the first page is amended and restated to refer to "$173,330,000".

	b.
	Paragraph 4
of the Purchase Agreement, prior to subparagraph 4(c) thereof, is amended and restated as follows:

	
4.
	Security
for Chiron's Obligations.    Chiron shall be excused from the requirements set forth below in the various subparagraphs
of this Paragraph 4, if (but only if) on or prior to the first Business Day in September, 2007: (1) Chiron shall have purchased or caused an Applicable Purchaser to have purchased
BNPLC's interest in the Property pursuant to subparagraph, and Chiron shall have paid to BNPLC all amounts required in connection with the purchase; or (2) Chiron shall have delivered to BNPLC
a new amended and restated guarantee by Guarantor (or by any surviving corporation that may result from a merger of Guarantor with another Person) of the payment obligations of Chiron under the Ground
Lease, the Lease and this Agreement in the form attached hereto as Exhibit J, expiring no earlier than September 30, 2009; or (3) Chiron shall have
obtained from BNPLC and all Participants a waiver in writing of the requirements of this Paragraph 4 (it being understood that, if asked for such a waiver, BNPLC or any of the Participants may
in its sole and absolute discretion decline to provide the waiver, as more 

7

 

particularly
provided in subparagraph 4.(b) below). Unless Chiron is so excused, Chiron shall comply with the following: 

	(a)
	Provisions
for Financial Covenants or Security.    Chiron must do one (but only one) of the following:

	i.
	after
satisfying the conditions set forth in subparagraph 4.(b), and no later than the first Business Day of September, 2007, Chiron must execute and deliver an amendment
of this Agreement (the "Financial Covenant Amendment"), committing Chiron to comply with financial covenants and pricing set forth therein; or

	ii.
	after
satisfying the conditions set forth in subparagraph 4.(c), and no later than the first Business Day of September, 2007, Chiron must execute and deliver Pledge
Documents (as defined below) and thereby grant to BNPLC before a first priority perfected security interest in Qualified Securities or in a Qualified Right to Stock Sale Proceeds; or

	iii.
	no
later than the first Business Day of September, 2007, Chiron must deliver immediately available funds to BNPLC in an amount equal to Stipulated Loss Value
("Restricted Funds"), which BNPLC shall be entitled to hold as security and apply as hereinafter provided.

	(b)
	Conditions
to Chiron's Use of a Financial Covenant Amendment.    Before Chiron may choose to satisfy the requirements of the preceding
subparagraph 4(a)(i) by delivering a Financial Covenant Amendment (in lieu of Pledge Documents or the delivery of Restricted Funds to BNPLC), the following condition must be satisfied: 

No
later than ten Business Days prior to the first Business Day of September, 2007 Chiron must have received the prior approval of BNPLC and each of the Participants of the form and substance of the
Financial Covenant Amendment, including the financial covenants and pricing provided therein that will be incorporated into this Agreement and the Lease. The financial covenants and pricing contained
in the Financial Covenant Amendment shall be consistent with financial covenants and pricing consistent with then market conditions for similar quality credits (compared to Chiron) and remaining tenor
to the Lease, Ground Lease and Purchase Agreement. Neither BNPLC nor Participants shall, however, be required to approve of any such amendment or of any financial covenants or pricing therein proposed
by Chiron before the same are in form and substance satisfactory to each of BNPLC and the Participants in its sole and absolute discretion. To facilitate Chiron's satisfaction of this condition, BNPLC
will cause its counsel to prepare and submit drafts of a Financial Covenant Amendment, if Chiron requests such drafts from BNPLC in a notice given to BNPLC and the Participants no later than
June 1, 2007, and if Chiron unconditionally confirms in such notice that Chiron will pay the Attorney's Fees and any other reasonable costs incurred by BNPLC or the Participants in connection
with the preparation or approval of the drafts or otherwise incurred in responding to the request. 

	c.
	In
addition to the foregoing, all other requirements of Paragraph 4 are fully and completely reinstated (notwithstanding the terms of Section 1 of the First Amendment to
Purchase Agreement dated September 1, 1999), and all other references in Paragraph 4 to "September, 1999" are amended and restated to refer to "September, 2007". The reference in
Subparagraph 4.(c) to "June 1, 1999" is amended and restated to refer to "June 1, 2007".

	d.
	The
notice address of each of the parties referenced in Paragraph 10.(a)(iii) is modified to the same addresses given in the Lease (as modified above).

	e.
	Exhibit J
is amended and restated with Exhibit J attached hereto. 

8

  

	6.
	Legal
Description.    The legal description of the Land attached to the Lease, Ground Lease, and Purchase Agreement is amended and restated with
the legal description attached as Exhibit A hereto.

	7.
	Fees.    Concurrently
herewith, Chiron shall pay to BNPLC the following fees, each of which are deemed fully earned by BNPLC and
non-refundable to Chiron:

	a.
	an
upfront fee as provided in the letter agreement dated May 15, 2003 between BNPLC and;

	b.
	a
best efforts arranger fee as provided in the letter agreement dated May 15, 2003 between BNPLC.

	8.
	Representations
and Covenants by BNPLC Concerning Accounting Matters.

	a.
	BNPLC
represents that to the knowledge of BNPLC the facts disclosed in the financial statements and other documents listed in Exhibit B were (as of
their respective dates) true, correct and complete in all material respects. Copies of those financial statements and documents were provided by or behalf of BNPLC to Chiron prior to the date hereof
to permit Chiron to determine the appropriate accounting for Chiron's relationship with BNPLC under FASB Interpretation No. 46, Consolidation of Variable Interest
Entities ("FIN 46").

	b.
	BNPLC
also represents that to the knowledge of BNPLC the fair value of the Property and of other properties, if any, leased to Chiron by BNPPLC (collectively, whether one or more, the
"Properties Leased to Chiron") are, as of the date hereof, less than half of the total of the fair values of all assets of BNPLC, excluding any assets
of BNPLC which are held within a silo. Further, BNPLC represents that none of the Properties Leased to Chiron are, as of the date hereof, held within a silo. Consistent with the directions of Chiron
(based upon the current interpretation of FIN 46 by Chiron and its auditors), and for purposes of this representation only:

	!
	"held within a silo" means, with respect to any asset or group of assets leased by BNPLC to a single lessee or group of affiliated
lessees, that BNPLC has obtained funds equal to or in excess of 95% of the fair value of the leased asset or group of assets to acquire or maintain its investment in such asset or group of assets
through non-recourse financing or other contractual arrangements (such as targeted equity or bank participations), the effect of which is to leave such asset or group of assets (or
proceeds thereof) as the only significant asset or assets of BNPLC at risk for the repayment of such funds;

	!
	"fair value" means, with respect to any asset, the amount for which the asset could be bought or sold in a current transaction negotiated
at arms length between willing parties (that is, other than in a forced or liquidation sale);

	!
	with
respect to the Properties Leased by Chiron (regardless of how BNPLC accounts for the leases of the Properties Leased by Chiron), and with respect to other assets that are subject
to leases accounted for by BNPLC as operating leases pursuant to Financial Accounting Standards Board Statement 13 ("FAS 13"), fair value is
determined without regard to residual value guarantees, remarketing agreements, non-recourse financings, purchase options or other contractual arrangements, whether made by BNPLC with
Chiron or with other parties, that might otherwise impact the fair value of such assets;

	!
	with
respect to assets, other than Properties Leased by Chiron, that are subject to leases accounted for by BNPLC as leveraged leases pursuant to FAS 13, fair value is determined
on a gross basis prior to the application of leveraged lease accounting, recognizing that equity investments made by BNPLC in its assets subject to leveraged lease accounting should be grossed up in
applying this test (however; equity investments made by BNPLC in another legal entity should not be grossed up in applying this test); 

9

 

	!
	with
respect to assets, other than Properties Leased by Chiron, that are subject to leases accounted for by BNPLC as direct financing leases pursuant to FAS 13, fair value is
determined as the sum of the fair values (considering current interest rates at which similar loans would be made to borrowers with similar credit ratings and for the same remaining maturities) of the
corresponding finance lease receivables and related unguaranteed residual values.

	c.
	BNPLC
covenants that, as reasonably requested by Chiron from time to time with respect to any accounting period during which the Lease is or was in effect, BNPLC will provide to Chiron
confirmation of facts concerning BNPLC and its assets as reasonably necessary or appropriate to permit Chiron to determine the proper accounting for the Lease (including updates of the facts set forth
in the documents provided to Chiron as described in clause a. above and of the facts set forth in clause b. above, and including updates of the information described on
Exhibit B); except that BNPLC will not be required by this provision to (x) provide any information that is not in the possession or control of BNPLC or its Affiliates,
(y) disclose the specific terms and conditions of its leases or other transactions with other parties, or the names of such parties, or (z) disclose any other information that is
protected from disclosure by confidentiality provisions in favor of such other parties or would be protected if their agreements with BNPLC contained confidentiality provisions similar in scope and
substance to the confidentiality provisions set forth herein in favor of Chiron and its Affiliates. BNPLC will represent that information provided by it pursuant to this clause is true, correct and
complete in all material respects, but only to the knowledge of BNPLC as of the date it is provided, utilizing the form of the certificate attached hereto as Exhibit C (signed by an officer of
BNPLC), which such certificate shall be provided by BNPLC five business days before each of Chiron's fiscal quarter ends, or periodically within five business days of reasonable written request
therefor by Chiron as provided above, or such longer period of time as may be reasonably necessary under the circumstances in order for BNPLC to confirm such information.

	d.
	Although
the representations required of BNPLC by this subparagraph are intended to cover facts, it is understood and agreed (consistent
with subparagraph 7(f) of the Lease) that BNPLC has not made and will not make any representation or warranty as to the proper accounting by Chiron or its Affiliates of the Lease or as to other
accounting conclusions.

	9.
	Reservation
of Rights.    Chiron acknowledges and agrees that the execution and delivery by BNPLC and the Participants of this Amendment shall
not be deemed to create a course of dealing or otherwise obligate BNPLC or the Participants to enter into amendments under the same, similar or any other circumstances in the future, except as
otherwise provided in this Amendment and Paragraph 6 of the Participation Agreement.

	10.
	Successors
and Assigns.    All of the covenants, agreements, terms and conditions to be observed and performed by the parties hereto shall be
applicable to and binding upon their respective heirs, personal representatives, successors and, to the extent assignment is permitted under the Lease, their respective assigns.

	11.
	Execution
in Counterparts.    To facilitate execution, this Amendment may be executed in as many identical counterparts as may be required. It
shall not be necessary that the signature of, or on behalf of, each party or consenting party, or that the signature of all persons required to bind any party, appear on each counterpart. All
counterparts, taken together, shall collectively constitute a single instrument. It shall not be necessary in making proof of this Amendment to produce or account for more than a single counterpart
containing the respective signatures of, or on behalf of, each of the parties and the consenting parties hereto. Any signature page to any counterpart may be detached from such counterpart without
impairing the legal effect of the signatures thereon and 

10

 

thereafter
attached to another counterpart identical thereto except having attached to it additional signature pages. Signing and sending a counterpart (or a signature page detached from the
counterpart) by facsimile or other electronic means to another party will have the same legal effect as signing and delivering an original counterpart to the other party. A copy (including a copy
produced by facsimile or other electronic means) of any signature page that has been signed by or on behalf of a party to this Amendment shall be as effective as the original signature page for the
purpose of proving such party's agreement to be bound. 

	12.
	Miscellaneous.    Words
of any gender used in the Lease, the Purchase Agreement or the Ground Lease or any amendment to any of them, including
this Amendment itself (collectively, the "Operative Documents") shall be held and construed to include any other gender, and words in the singular
number shall be held to include the plural and vice versa, unless the context otherwise requires. References in any Operative Document to Paragraphs, subparagraphs, Sections, subsections or other
subdivisions shall refer to the corresponding Paragraphs, subparagraphs, Sections, subsections or subdivisions of that Operative Document, unless specific reference is made to another document or
instrument. References in any Operative Document to any Schedule or Exhibit shall refer to the corresponding Schedule or Exhibit attached to that Operative Document, which shall be made a part thereof
by such reference. All capitalized terms used in each Operative Document which refer to other documents shall be deemed to refer to such other documents as they may be renewed, extended, supplemented,
amended or otherwise modified from time to time, provided such documents are not renewed, extended or modified in breach of any provision contained in the Operative Documents or, in the case of any
other document to which BNPLC is a party or of which BNPLC is an intended beneficiary, without the consent of BNPLC. All accounting terms used but not specifically defined in any Operative Document
shall be construed in accordance with GAAP. The words "this [Agreement]", "herein", "hereof", "hereby", "hereunder" and words of similar import when used in each Operative
Document refer to that Operative Document as a whole and not to any particular subdivision unless expressly so limited. The phrases "this Paragraph", "this subparagraph", "this Section", "this
subsection" and similar phrases used in any Operative Document refer only to the Paragraph, subparagraph, Section, subsection or other subdivision described in which the phrase occurs. As used in the
Operative Documents the word "or" is not exclusive. As used in the Operative Documents, the words "include", "including" and similar terms shall be construed as if followed by "without limitation to".
The rule of ejusdem generis shall not be applied to limit the generality of a term in any of the Operative Documents when followed by specific examples.
When used to qualify any representation or warranty made by a Person, the phrases "to the knowledge of [such Person]" or "to the best knowledge of [such
Person]" are intended to mean only that such Person does not have knowledge of facts or circumstances which make the representation or warranty false or misleading in some material
respect; such phrases are not intended to suggest that the Person does indeed know the representation or warranty is true.

	13.
	Disclosure.    BNPLC
and each Participant (and each of their respective officers, directors, employees, accountants, attorneys and other
advisors, agents and representatives) may disclose to any and all Persons, to the extent required by applicable laws or as determined to be reasonably necessary by BNPLC or any Participant to comply
with applicable laws, upon written reasonable request therefor (and following advance written notice to Chiron of BNPLC's or such Participant's intent to make such disclosure), the U.S. tax treatment
and U.S. tax structure of the transactions contemplated hereby and such materials (including opinions and other tax analyses) that are provided by third parties to any of them relating to such U.S.
tax treatment and U.S. tax structure, as may be required to comply with applicable laws. 

11

 
[Signature pages follow.]

12

 

        IN
WITNESS WHEREOF, this Second Amendment has been executed as of July 1, 2003. 

	 
	 	 
	 	 

	 	 	CHIRON CORPORATION
	+	 	 	 	 
	 	 	By:	 	/s/  JOEL R. JUNG      

	 	 	Printed Name: Joel R. Jung

Title: Vice President & Treasurer

13

 

[Continuation
of signature pages to Second Amendment dated to be effective as of July 1, 2003] 

	 
	 	 
	 	 

	 	 	BNP PARIBAS LEASING CORPORATION,

a Delaware corporation
	

 	
 	

By:	
 	

/s/  LLOYD G. COX      

	 	 	Printed Name: Lloyd G. Cox

Title: Managing Director

14

 

[Continuation
of signature pages to Second Amendment dated to be effective as of July 1, 2003] 

        The
undersigned Participant hereby consents to the foregoing Amendment. 

	 
	 	 
	 	 

	 	 	BNP PARIBAS
	

 	
 	

By:	
 	

/s/  PIERRE NICHOLAS ROGERS      

	 	 	Printed Name: Pierre Nicholas Rogers

Title: Managing Director
	

 	
 	

By:	
 	

/s/  RAFAEL C. LUMANIAN      

	 	 	Printed Name: Rafael C. Lumanian

Title: Director

15

 

[Continuation
of signature pages to Second Amendment dated to be effective as of July 1, 2003] 

        The
undersigned Participant hereby consents to the foregoing Amendment. 

	 
	 	 
	 	 

	 	 	CREDIT SUISSE FIRST BOSTON, CAYMAN ISLANDS BRANCH
	

 	
 	

By:	
 	

/s/  KARL M. STUDER      

	 	 	Printed Name: Karl M. Studer

Title: Director
	

 	
 	

By:	
 	

/s/  BILL O'DALY      

	 	 	Printed Name: Bill O'Daly

Title: Director

16

 

[Continuation
of signature pages to Second Amendment dated to be effective as of July 1, 2003] 

        The
undersigned Participant hereby consents to the foregoing Amendment. 

	 
	 	 
	 	 

	 	 	UBS AG, Cayman Islands Branch
	 	 	By:	 	/s/  WILFRED V. SAINT      

	 	 	Printed Name: Wilfred V. Saint

Title: Associate Director

            Banking Products Services, US
	

 	
 	

By:	
 	

/s/  PATRICIA O'KICKI      

	 	 	Printed Name: Patricia O'Kicki

Title: Director

17

 
 

Exhibit A
  
    Legal Description    
    

REAL
PROPERTY IN CITY OF EMERYVILLE, COUNTY OF ALAMEDA, STATE OF CALIFORNIA DESCRIBED AS FOLLOWS: 

LOT
ONE: 

"ADJUSTED
LOT 1", AS DESCRIBED IN THE CERTIFICATE OF COMPLIANCE AND LOT LINE ADJUSTMENT RECORDED FEBRUARY 1, 2002, SERIES NO. 2002051905, OFFICIAL RECORDS, BEING ALL OF "RESULTING CHIRON LOT 1" AS
SAID LOT IS DESCRIBED IN THE LOT LINE ADJUSTMENT RECORDED NOVEMBER 13, 2001, SERIES NO. 2001441478, OFFICIAL RECORDS, AND A PORTION OF LOT 2 AS SHOWN ON THE PARCEL MAP ENTITLED, "PARCEL MAP NO. 7032,
CHIRON LIFE SCIENCES CENTER PHASE I", FILED SEPTEMBER 18, 1996 IN MAP BOOK 225, PAGES 35 THROUGH 37, ALAMEDA COUNTY RECORDS, MORE PARTICULARLY DESCRIBED AS FOLLOWS: 

ALL
OF SAID "RESULTING CHIRON LOT 1" (2001441478); 

AND
A PORTION OF SAID LOT 2 (225 PM 35) MORE PARTICULARLY DESCRIBED AS FOLLOWS: 

BEGINNING
AT THE MOST WESTERN CORNER OF SAID LOT 2 (225 PM 35), THENCE ALONG THE BOUNDARY OF SAID LOT 2 THE FOLLOWING FOUR COURSES: 

	I.
	NORTH
72°28'00" EAST 98.80 FEET; 
	II.
	NORTH
17°32'00" WEST 55.00 FEET; 
	III.
	NORTH
72°28'00" EAST 179.25 FEET; 
	IV.
	SOUTH
27°46'45" EAST 177.83 FEET; 

THENCE
LEAVING THE BOUNDARY OF SAID LOT 2, SOUTH 72°28'00" WEST 106.08 FEET; THENCE NORTH 17°32'00" WEST 22.00 FEET; THENCE SOUTH 72°28'00" WEST 203.60 FEET TO A
POINT ON THE BOUNDARY OF SAID LOT 2; THENCE ALONG THE BOUNDARY OF SAID LOT 2, NORTH 17°32'00" WEST 97.99 FEET TO THE POINT OF BEGINNING. 

ASSESSOR'S
PARCEL NO. 049-1041-070-02 

LOT
TWO: 

"ADJUSTED
LOT 2", AS DESCRIBED IN THE CERTIFICATE OF COMPLIANCE AND LOT LINE ADJUSTMENT RECORDED FEBRUARY 1, 2002, SERIES NO. 2002051905, OFFICIAL RECORDS, BEING A PORTION OF LOT 2 AS SHOWN ON THE
PARCEL MAP ENTITLED, "PARCEL MAP NO. 7032, CHIRON LIFE SCIENCES CENTER PHASE I", FILED SEPTEMBER 18, 1996 IN MAP BOOK 225, PAGES 35 THROUGH 37, ALAMEDA COUNTY RECORDS, MORE PARTICULARLY DESCRIBED AS
FOLLOWS: 

ALL
OF SAID LOT 2 (225 PM 35) EXCEPTING THEREFROM THE FOLLOWING DESCRIBED PARCEL: 

BEGINNING
AT THE MOST WESTERN CORNER OF SAID LOT 2 (225 PM 35), THENCE ALONG THE BOUNDARY OF SAID LOT 2 THE FOLLOWING FOUR COURSES: 

	I.
	NORTH
72°28'00" EAST 98.80 FEET; 
	1
	NORTH
17°32'00" WEST 55.00 FEET; 
	2
	NORTH
72°28'00" EAST 179.25 FEET; 
	3
	SOUTH
27°46'45" EAST 177.83 FEET; 

THENCE
LEAVING THE BOUNDARY OF SAID LOT 2, SOUTH 72°28'00" WEST 106.08 FEET; THENCE NORTH 17°32'00" WEST 22.00 FEET; THENCE SOUTH 72°28'00" WEST 203.60 FEET TO A
POINT ON THE BOUNDARY OF SAID LOT 2; THENCE ALONG THE BOUNDARY OF SAID LOT 2, NORTH 17°32'00" WEST 97.99 FEET TO THE POINT OF BEGINNING. 

ASSESSOR'S
PARCEL NO. 049-1041-071-02 

 
 

Exhibit B    
    

	A.
	Unaudited
balance sheet of BNPPLC dated April 30, 2003.

	B.
	Unaudited
income statement of BNPPLC dated April 30, 2003.

	C.
	Portfolio
listing dated April 30, 2003, listing individual lease transactions by origination date, expiration date, lease balance, share held by BNPPLC or its Affiliates and
share held by third party participants.

	D.
	RAROC
model of BNPPLC's portfolio as of April 30, 2003, run under several sets of assumptions.

	E.
	Memorandum
dated March 10, 2003 to Lloyd Cox from Clint Shouse, summarizing features of BNPPLC's in the participation structure, including the earlier memorandum attached
thereto to Lloyd Cox from Clint Shouse dated February 12, 2003. 

 
 

Exhibit C
  
    Form of Certificate    
    

Chiron
Corporation

4560 Horton Street

Emeryville, California 94608-2916 

Gentlemen:

        This
Certificate is furnished pursuant to that certain Lease Agreement dated as of June 28, 1996 (as amended, the "Lease") and that
certain Second Amendment dated as of July 1, 2003 (the "Second Amendment"), the terms defined in the Lease and Second Amendment being used herein
as therein defined. The undersigned, as                        of BNP Paribas Leasing Corporation ("BNPLC"), does hereby certify
that the following are true, correct and complete in all material respects,
but only to the knowledge of BNPLC as of the date hereof: 

	1.
	BNPLC
represents that to the knowledge of BNPLC the facts disclosed in the financial statements and other documents listed in Exhibit attached hereto were
(as of their respective dates) true, correct and complete in all material respects. Copies of those financial statements and documents were provided by or behalf of BNPLC to Chiron prior to the date
hereof to permit Chiron to determine the appropriate accounting for Chiron's relationship with BNPLC under FASB Interpretation No. 46, Consolidation of Variable Interest
Entities ("FIN 46").

	2.
	BNPLC
also represents that to the knowledge of BNPLC the fair value of the Property and of other properties, if any, leased to Chiron by BNPPLC (collectively, whether one or more, the
"Properties Leased to Chiron") are, as of the date hereof, less than half of the total of the fair values of all assets of BNPLC, excluding any assets
of BNPLC which are held within a silo. Further, BNPLC represents that none of the Properties Leased to Chiron are, as of the date hereof, held within a silo. 

        Although
the representations required of BNPLC by this certificate are intended to cover facts, it is understood and agreed (consistent
with subparagraph 7(f) of the Lease) that BNPLC has not made and will not make any representation or warranty as to the proper accounting by Chiron or its Affiliates of the Lease or as to other
accounting conclusions. 

        Executed
this            day of                        ,
20    . 

	 
	 	 
	 	 
	 	 

	 	 	BNP Paribas Leasing Corporation
	

 	
 	

By:	
 	

 	
 	

 
	 	 	 	 	

	 	 	 	 	Name:	 	 
	 	 	 	 	 	 	

	 	 	 	 	Title:	 	 
	 	 	 	 	 	 	

 
 

Exhibit J
  
    Form of Replacement Guaranty of Novartis, AG
  
    GUARANTY    
    

        This
Guaranty is made effective as of July 1, 2003 by Novartis, AG (the "Guarantor") in favor of BNP Paribas Leasing Corporation, a
Delaware corporation, which is wholly owned by BNP Paribas ("BNPLC"), and in favor of BNP Paribas, Credit Suisse First Boston, UBS AG, Cayman Islands
Branch and any other banks or financial institutions that become "Participants" with BNPLC (as defined in the Lease). BNPLC and such Participants are sometimes hereinafter referred to collectively as
the "Banks". 

        WHEREAS,

        At
the request of Chiron Corporation, a Delaware corporation ("Chiron"), in which the Guarantor is a major shareholder, BNPLC has advanced
funds to Chiron pursuant to the "Lease and Purchase Agreements" (as defined hereinafter), and BNPLC and the Participants have agreed to make certain modifications to the Lease and Purchase Agreements
pursuant to the Second Amendment of even date herewith (the "Amendment"), and 

        WHEREAS,

        it
is a condition of BNPLC and the Participants to their execution of the Amendment, that the Guarantor guarantee the obligations of Chiron under the Lease and Purchase Agreements, 

        NOW,
THIS GUARANTY WITNESSES as follows: 

	1.
	Guaranty.    The
Guarantor irrevocably and unconditionally undertakes to secure to BNPLC the due and punctual payment of all money that may
become due from time to time to BNPLC from Chiron under or as provided in the following documents, as amended from time to time (the "Lease and Purchase
Agreements"):

	(a)
	the
Ground Lease dated as of June 28, 1996 (but effective as of July 1, 1996), providing (among other things) for the sublease by Chiron to BNPLC of land described
therein (the "Land");

	(b)
	the
Lease Agreement dated as of June 28, 1996 (but effective as of July 1, 1996), providing (among other things) for the construction of improvements on the Land by
Chiron with funds advanced by BNPLC (which such construction has been completed) and the use and sublease by Chiron from BNPLC of the Land and the improvements (the
"Lease"); and

	(c)
	the
Purchase Agreement dated as of June 28, 1996 (but effective as of July 1, 1996), providing (among other things) for the sale by BNPLC of Land and improvements
thereon to Chiron or to a third party designated by Chiron (the "Purchase Agreement"). 

        The
Guarantor therefore undertakes to pay on first demand of BNPLC any amount payable under or as provided in the Lease and Purchase Agreements up to a maximum total amount (the
"Maximum Amount") of USD $173,330,000 irrespective of the validity and the legal effects of the Lease and Purchase Agreements, waiving all rights of
objection and defense arising therefrom upon receipt of the written request for payment and the statement in writing by BNPLC that Chiron has not made payment on the date(s) specified and the amount
called under the Guaranty. 

	2.
	BNPLC's
Obligation to Distribute Payments to Participants:    Guarantor has been advised that the following agreements (the
"Participation Agreements") establish the respective rights and obligations of the Banks concerning advances of funds to Chiron required by the Lease
and 

Purchase
Agreements and concerning the allocation among the Banks of payments required of Chiron by the Lease and Purchase Agreements: 

	(a)
	the
Participation Agreement between BNPLC and BNP Paribas (as successor in interest to Banque Nationale de Paris) dated as of June 28, 1996 (but effective as of July 1,
1996), providing (among other things) for (1) the advance by BNP Paribas of a percentage ("BNP Paribas' Percentage") of the funds that Chiron may
request from BNPLC under the Lease and Purchase Agreements and (2) the payment to BNP Paribas of BNP Paribas' Percentage of certain payments received by BNPLC from Chiron under the Lease and
Purchase Agreements;

	(b)
	the
Participation Agreement between BNPLC and Credit Suisse First Boston (as successor in interest to Credit Suisse) dated as of June 28, 1996 (but effective as of
July 1, 1996), providing (among other things) for (1) the advance by Credit Suisse First Boston, Cayman Islands Branch of a percentage ("Credit Suisse's
Percentage") of the funds that Chiron may request from BNPLC under the Lease and Purchase Agreements and (2) the payment to Credit Suisse of Credit Suisse's Percentage
of certain payments received by BNPLC from Chiron under the Lease and Purchase Agreements; and

	(c)
	the
Participation Agreement between BNPLC and UBS AG, Cayman Islands Branch (as successor in interest to Union Bank of Switzerland) dated as of June 28, 1996 (but effective as
of July 1, 1996), providing (among other things) for (1) the advance by UBS AG, Cayman Islands Branch of a percentage ("UBS AG's
Percentage") of the funds that Chiron may request from BNPLC under the Lease and Purchase Agreements and (2) the payment to UBS AG, Cayman Islands Branch of UBS AG's
Percentage of certain payments received by BNPLC from Chiron under the Lease and Purchase Agreements. 

        Except
as provided in the next paragraph, any demand for payment made by BNPLC upon Guarantor under this Guaranty will constitute a demand made not only for BNPLC itself, but also on
behalf of Participants. Further, if BNPLC does make such a demand for itself and for Participants, BNPLC shall distribute a portion of any payments BNPLC receives from Guarantor to Participants in
accordance with the Participation Agreements, and BNPLC shall also distribute a portion of any payments BNPLC receives from Guarantor to Participants in accordance with the Participation Agreements. 

	3.
	Separate
Demands by BNPLC and Participants:    If Chiron shall fail to pay an amount for which BNPLC can demand payment from Guarantor under this
Guaranty, the Banks may agree among themselves to each make a separate demand directly upon Guarantor. However, to be effective for purposes of this Guaranty, any such agreement by the Banks must be
in writing; must be provided to Guarantor before BNPLC makes a demand upon Guarantor for itself and for Participants; and must specify the respective amounts that BNPLC and each Participant will for
itself demand of Guarantor. Also, the total of all amounts specified in any such agreement as amounts that will be demanded of Guarantor must not exceed (before any addition required by the next
paragraph) Guarantor's maximum liability. If Guarantor receives an agreement among the Banks that satisfies the requirements set forth in the preceding sentences, Guarantor shall honor any separate
demands made by BNPLC and Participants in accordance with such agreement by making payments directly to BNPLC and Participants, rather than by making a single payment to BNPLC.

	4.
	Gross
Up:    Subject to the understanding that Guarantor's liability will not exceed (except as provided in the next sentence) the Maximum
Amount, Guarantor hereby expressly undertakes and secures that payments under this Guaranty will not be less than as stipulated in the Lease and Purchase Agreements. In implementation of this
undertaking and in case Swiss withholding taxes are imposed in respect of payments made under this Guaranty, the Guarantor undertakes, as a separate and independent obligation, irrespective of the
Maximum Amount, to pay additional amounts equal to such withholding taxes so that the net payments 

received
by BNPLC shall equal the amount actually owed by Chiron to BNPLC under the Lease and Purchase Agreements. 

	5.
	Guarantor's
Obligations Continuing:    The Guarantor's obligations under this Guaranty are and will remain in full force and effect by way of
continuing security until no sum remains payable under the Lease and Purchase Agreements. Furthermore, these obligations of the Guarantor are additional to, and not instead of, any security or other
guarantee or indemnity at any time existing in favor of BNPLC, whether from the Guarantor or otherwise. The Guarantor irrevocably waives all notices and demands whatsoever. However, Guarantor shall
not have to make any payment requested for the first time after December 31, 2009 by BNPLC (as provided in the last sentence of Paragraph 1) or by BNPLC or Participants (as provided in
accordance with an agreement described in Paragraph 3).

	6.
	Repayments
in Liquidation:    If any payment received by BNPLC or payable to BNPLC under the Lease and Purchase Agreements is, on the liquidation
or insolvency of Chiron, excused, reduced or avoided under any laws relating to liquidation or insolvency, such payment or the excuse, reduction or avoidance of such payment will not be considered as
having discharged or diminished the liability of the Guarantor and this Guaranty will continue to apply as if such payment had at all times remained owning by Chiron.

	7.
	Status
of Guaranty:    The payment obligations of the Guarantor under this Guaranty constitute direct, unconditional and unsecured obligations of
the Guarantor and rank and will rank pari passu with all other outstanding unsecured and unsubordinated indebtedness and monetary obligations of the
Guarantor, present or future, including those in respect of deposits, but, in the event of insolvency, bankruptcy, reorganization or similar proceedings, only to the extent permitted by applicable
laws to creditors' rights.

	8.
	Power
to Execute:    The Guarantor hereby warrants, represents and covenants that it has all corporate power, and has taken all necessary
corporate or other steps, to enable it to execute, deliver and perform this Guaranty, and that this Guaranty constitutes a legal, valid and binding obligation of the Guarantor in accordance with its
terms.

	9.
	Transfer
of Rights:    If and to the extent the Guarantor has made payment under the Guaranty the Guarantor is entitled to the transfer of
BNPLC's rights against Chiron and the right of recovery from Chiron. However, the Guarantor shall not by virtue of this Guaranty be entitled to the transfer of any rights of BNPLC or claim in
competition with BNPLC until all amounts which may be payable under the Lease and Purchase Agreements have been paid in full.

	10.
	Governing
Law and Jurisdiction:    This Guaranty is governed by and shall be construed in accordance with Swiss law. Exclusive jurisdiction and
venue for any legal proceeding brought to enforce this Guaranty will be in Basle, Switzerland. This present Guaranty supersedes the one issued by Novartis, AG, Basel/Switzerland on August 31,
1999 amounting to USD $172,572,542.12, which will be returned to Novartis, AG. 

	 
	 	 
	 	 

	 	 	NOVARTIS, AG
	

 	
 	

By:	
 	

 
	 	 	 	 	

QuickLinks

Exhibit 10.004

SECOND AMENDMENT

Exhibit A Legal Description

Exhibit B

Exhibit C Form of Certificate

Exhibit J Form of Replacement Guaranty of Novartis, AG GUARANTYQuickLinks
 -- Click here to rapidly navigate through this document

 
 

Exhibit 10.212    
    

	CONFIDENTIAL	 	REDACTED VERSION

 
 

[***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN
  OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
  RESPECT TO THE OMITTED PORTIONS.
  
  CONTRACT
MANUFACTURING AGREEMENT    
    

        THIS CONTRACT MANUFACTURING AGREEMENT (the "Agreement") is made and entered into as of June 12, 2003
("Date of Agreement"), by and between: 

        Chiron S.r.l., with its registered offices at Via Fiorentina 1, 53100 Siena, Italy, 

        and

        Chiron Behring GmbH & Co., with its registered offices at Emil von Behring Strasse 76, 35041 Marburg, Germany, together with Chiron
S.r.l.. hereafter referred to as "Chiron"; 

        SynCo Bio Partners B.V., with its registered offices at Paasheuvelweg 30, 1105 BJ Amsterdam-Zuidoost, The Netherlands, hereafter referred
to as "SynCo"; 

Background  

	—	 	Chiron has developed a broad line of novel adult and pediatric vaccines for viral and bacterial infectious diseases, including but not limited to Chiron's Meningococcal C conjugate vaccine ("Menjugate®");
	

—	
 	

SynCo operates a biopharmaceutical manufacturing plant in Amsterdam, The Netherlands;
	

—	
 	

SynCo has prior to this Agreement provided Chiron services related to the production of Chiron's Menjugate® designated for the European market on the basis of that certain contract manufacturing agreement dated July 26, 2001;
	

—	
 	

Chiron desires to register and launch Chiron's Menjugate® in the USA;
	

—	
 	

Chiron wishes to contract SynCo to provide services related to the production of Chiron's Menjugate®, for the European and US market, in quantities and at times to be separately agreed upon between the Parties in accordance with this
Agreement;
	

—	
 	

SynCo is willing to use its personnel, expertise and facilities to provide such services to Chiron in accordance with the terms of this Agreement;
	

—	
 	

The Parties shall simultaneously with this Agreement enter into that certain agreement related to the adjustments to be made to the Plant, in order to have this facility comply with all US Food and Drug Administration requirements (the "FDA Compliance Agreement") and any and all obligations of either party under this Agreement are subject to the other party fulfilling its obligations under such FDA Compliance Agreement;

        NOW,
THEREFORE, in consideration of the premises, the mutual covenants, terms and conditions hereinafter set forth, THE PARTIES AGREE AS FOLLOWS: 

Article 1—Definitions  

        For the purpose of this Agreement the following terms shall be defined as follows: 

	1.1.
	"Affiliate" means with respect to either Party: any company, entity, joint venture or similar business arrangement which is controlled
by, controlling or under common control with such Party, 

 

and
shall include without limitation any company fifty percent or more of whose voting stock or participating profit interest is owned or controlled, directly or indirectly, by such Party, and any
company which owns or controls, directly or indirectly, fifty percent or more of such Party. 

	1.2.
	"BPRs" means: the batch production records and other documents providing the manufacturing history of a batch of a Product.

	1.3.
	"Confidential Information" means: (a) all information disclosed by either Party in writing and designated confidential and
(b) all information disclosed orally by either Party and confirmed in writing and designated confidential by such disclosing Party within thirty (30) days after such disclosure.

	1.4.
	"GMP" means: European Good Manufacturing Practices for Medicinal Products as in effect from time to time.

	1.5.
	"Material" means: the working cell banks and specific reagents as required for the manufacture of the Products in accordance with the
relevant Specifications, provided that commercially available raw materials are excluded from Material.

	1.6.
	"Parties" and "Party" means: SynCo and Chiron and SynCo or Chiron, respectively, as
the context may require.

	1.7.
	"Patents" means all patents owned by or licensed (with a right to sublicense) to Chiron or any of its Affiliates claiming Technology.

	1.8.
	"Plant" means: SynCo's facility located at Paasheuvelweg 30, 1105 BJ Amsterdam-Zuidoost, The Netherlands.

	1.9.
	"Product" or "Products" means: any or all of the vaccine products or intermediate
products thereof listed on Appendix B.

	1.10.
	"Quality Agreement" means the quality agreement between the Parties in the form attached hereto as  Appendix F, as the same may be amended by the Parties from time to time.

	1.11.
	"Specifications" means: with respect to each Product, the specifications for such Product as set forth in  Appendix C, as such specifications may be amended by Chiron from time to time with the written approval of SynCo.

	1.12.
	"Technology" means: all inventions, discoveries, procedures, processes, methods, data, information, results, trade secrets and
know-how, whether patentable or otherwise, owned by or licensed (with a right to sublicense) to Chiron or any of its Affiliates as of the Date of Agreement or any time during the term of
this Agreement relating to the manufacture of the Products and shall include, without limitation, the Specifications.

	1.13.
	"USGMP" means: United States Good Manufacturing Practices as described in the US Code or Federal Regulations as in effect from time
to time. 

Article 2—Manufacture and Delivery of Product  

	2.1.
	As
from [***] SynCo shall manufacture and supply to Chiron such quantities of Products as Chiron may from time
to time order in accordance with the terms of this Agreement.

	2.2.
	Attached
as Appendix D is Chiron's firm binding order for Products to be delivered in  [***]. SynCo hereby accepts such order. This firm order cannot be reduced
by Chiron. In the event Chiron requires additional
Products for the year [***], Chiron may request SynCo to manufacture such additional Products, but SynCo may reject or accept
such request for additional Products at its sole discretion, provided, however, that SynCo shall notify Chiron in writing of its decision

2

 

 [***] of receipt of such request from Chiron. Under no circumstances shall SynCo be obliged to accept such request for additional Products. 

	2.3.
	The
split between CRM197 and MenC for the years [***] shall be communicated in writing by Chiron to SynCo no
later than the [***], respectively. If such split has not been communicated in writing to SynCo before the date indicated in the
previous sentence, a firm binding order will have been deemed made with a spilt as indicated between brackets in Appendix D. For the avoidance of doubt, the split between CRM197 and MenC for
the year [***] has been described in Appendix D and this split is part of the firm binding order for the year  [***] and cannot be changed.

	2.4.
	For
the years [***], Chiron shall order Products in the quantities set out in  Appendix E, provided that Chiron may reduce or increase these quantities by
 [***], and provided further that in the event that the Plant  [***], Chiron shall have the right to reduce such quantities by  [***]
. In the event Chiron requires more than [***],
Chiron may request SynCo to manufacture such additional batches, but SynCo may reject or accept such request for additional batches at its sole discretion provided, however, that SynCo shall notify
Chiron in writing of its decision [***] of receipt of such request from Chiron. Under no circumstances shall SynCo be obliged to
manufacture more than [***].

	2.5.
	For
the years [***], Chiron shall provide SynCo with firm binding orders and rolling forecasts as follows. On
or before [***], Chiron shall provide SynCo with a firm binding order for Products to be delivered in the year  [***] and a forecast of Products to be
delivered in the years  [***]. On or before [***], Chiron shall provide SynCo
with a firm binding order for Products to be delivered in the year [***] and on or before  [***] Chiron shall provide SynCo with a firm binding order for
Products to be delivered in the years  [***]. If Chiron's firm binding order with respect to any of the years [***]  has not been received by SynCo prior to
the date it should have been received by SynCo as set out in this Article 2.5., Chiron will be deemed to have made a firm binding
order in the quantity as set forth in the forecast applicable for the relevant year(s). If no forecast is applicable to the relevant year, a firm binding order will have been deemed made in the
quantities (and with the split between CRM197 and MenC) as set out in Appendix E. Article 2.4. hereof applies to any and all firm binding
orders and forecasts.

	2.6.
	SynCo
shall deliver MenC Products [***]. The dates/periods of manufacture and delivery of CRM197 Products
shall be at SynCo's sole discretion, provided the manufacture and delivery shall take place within the relevant year and for the quantities set out in Chiron's firm binding orders.

	2.7.
	Any
and all Products shall be delivered by SynCo to Chiron Ex Works (Plant, Amsterdam, The Netherlands) according to Incoterms 2000 upon payment of the Products. Chiron guarantees
that it shall, within thirty (30) business days from the date on which SynCo advises Chiron that the Products are available for delivery and provided that Chiron has paid in full any and all
amounts in respect of such Products, accept delivery of such Products and transfer the Products from the Plant. Title to the Products shall pass to Chiron upon payment in full of any and all amounts
in respect of such Products. Notwithstanding anything to the contrary in this Agreement, ultimately 30 days from the date on which SynCo has advised Chiron that the Products are available for
delivery, the risks with respect to such Products transfers from SynCo to Chiron and SynCo accepts no responsibility whatsoever with respect to such Products as from such date. 

Article 3—Transfer of Technology and Material  

	3.1.
	Chiron
hereby grants to SynCo and guarantees that all its Affiliates are deemed to have granted to SynCo a non-exclusive,  [***] license under the Patents and any and all other rights to for the sole purpose of
using the Technology to manufacture
Products solely for Chiron in accordance with the terms and conditions of this Agreement. 

3

 
	3.2.
	Chiron
shall provide SynCo with the Specifications and all other relevant Technology or information necessary or conducive for the purpose of enabling SynCo to perform its
obligations under this Agreement.

	3.3.
	Chiron
shall furnish SynCo, [***], with the Material in sufficient quantities for the purpose of enabling
SynCo to perform its obligations under this Agreement. The Material shall remain the exclusive property of Chiron. SynCo shall not transfer the Material to any third party. The Material shall be
released by the Quality Assurance officer of Chiron. SynCo shall maintain records of usage of the Material, and shall inform Chiron of needs for additional quantities in a timely manner, and return to
Chiron any unused quantities of the Material upon request. Chiron shall provide SynCo with the Material in a timely manner for the purpose of enabling SynCo to perform its obligations under this
Agreement. A request by SynCo to Chiron to provide Material is in any way deemed to be made in a timely manner, if such request is made  [***] on which SynCo desires to receive such Material.

	3.4.
	Chiron
guarantees that all Material provided to SynCo is accompanied by a Certificate of Analysis by Chiron's Quality Assurance. 

Article 4—Regulatory Affairs and Quality Assurance  

 General  

	4.1.
	SynCo
shall exercise all reasonable skill, care and diligence in the performance of its duties under the Quality Agreement. In the event of a conflict between the Quality Agreement
and this Agreement, this Agreement prevails.

	4.2.
	SynCo
shall exercise all reasonable skill, care and diligence in the performance of its duties under this Agreement and shall carry out all responsibilities with recognized
professional standards and the requirements of GMP [***]. SynCo shall obtain and maintain all legally required permits in order
to manufacture the Products in the Plant. SynCo shall at the reasonable request of Chiron inform Chiron of all permits filed and their status with respect to approval.

	4.3.
	Chiron
shall provide to SynCo the release tests to be performed on the Products and SynCo shall perform such release testing in accordance with Chiron's reasonable written
instructions.

	4.4.
	Subject
to reasonable prior notice, Chiron's designated representatives may inspect those portions of the Plant used in the production of the Products for the purpose of determining
compliance with GMP [***] and with the terms of this Agreement at reasonable times during the production campaign of the
Products. SynCo shall provide full cooperation for these inspections.

	4.5.
	Chiron
shall have full and final responsibility for the release of each batch of Product manufactured by SynCo. 

 Registration and launch of Chiron's Menjugate® in the USA  

	4.6.
	The
Biological License Application (the "BLA") in respect of Chiron's Menjugate® shall be prepared and drafted by Chiron. SynCo shall provide Chiron with all information
required for the preparation of the BLA which is related to the Plant and the manufacturing activities (to be) performed by SynCo, provided SynCo possesses such information. To the extent that SynCo
does not possess such information SynCo shall use all reasonable endeavours to obtain such information and provide it to Chiron. The section in such BLA related to manufacturing activities (to be)
performed by SynCo shall be reviewed and, if approved, initialed by SynCo. Chiron shall have full and final responsibility for the BLA and for the timely submission thereof with the competent
regulatory authorities. 

4

 

Article 5—Warranties and Liability  

	5.1.
	SynCo
warrants that:

	a)
	the
Products shall be manufactured, packed, stored and delivered in compliance with this Agreement and all applicable laws, regulations, and orders, including GMP and,  [***]; without limiting the generality
of the foregoing, SynCo shall obtain and maintain in effect all required governmental
permits, licenses, and approvals applicable to the manufacture of the Products and shall produce the Products in accordance with all such permits, licenses, orders, applications and approvals;

	b)
	the
Material shall be received and stored in accordance with all applicable laws, regulations and orders and in accordance with the relevant specifications;

	c)
	on
the date of delivery thereof, the Products shall conform to the Specifications; and

	d)
	it
will not carry on activities in the Plant which could reasonably prevent the Products from being manufactured in accordance with all applicable laws, regulations, and orders,
including GMP, [***]. 

EXCEPT
AS OTHERWISE EXPRESSLY PROVIDED HEREIN, SYNCO MAKES NO REPRESENTATIONS, WARRANTIES, OR GUARANTEES, EXPRESS OR IMPLIED, FOR FITNESS FOR A PARTICULAR PURPOSE OR MERCHANTABILITY OF ANY OF THE
PRODUCTS MANUFACTURED BY IT. SYNCO EXPRESSLY DISCLAIMS ANY AND ALL RESPONSIBILITY IN RESPECT OF THE FITNESS FOR A PARTICULAR USE OR MERCHANTIBILITY OF ANY OF THE PRODUCTS MANUFACTURED BY IT. SYNCO
SHALL NOT BE LIABLE FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES IN ANY CASE OF NONCONFORMITY OF THE PRODUCT. NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INCIDENTAL OR CONSEQUENTIAL DAMAGES
ARISING FROM ANY ALLEGED OR ACTUAL BREACH OF THIS AGREEMENT. WITHOUT LIMITING THE FOREGOING, SYNCO DOES EXPRESSLY NOT WARRANT THE YIELD THAT WILL RESULT FROM THE MATERIAL OR THE YIELD OR QUANTITY OF
PRODUCT PER BATCH. 

	5.2.
	SynCo
shall as soon as reasonably possible replace, free of charge, any defective or non-conforming Product supplied to Chiron, provided Chiron notifies SynCo in writing
upon discovery of such defect or non-conformity within a period of sixty days after SynCo's Quality Assurance has approved the Product and provided further Chiron allows SynCo to evaluate
the claim and to test the said quantity of Product within a reasonable period of time, but not to exceed sixty days. Replacement of the Product by Synco pursuant to this paragraph 5.2 shall be
the sole remedy of Chiron against SynCo for defective or non-conforming Product.

	5.3
	If
the Parties disagree whether such Product is defective or non-conforming, then the Product in dispute will be tested and further analyzed by a qualified independent
testing laboratory reasonably acceptable to both Parties. Such laboratory's testing will determine, using representative samples, whether the quantity of the Product is defective or
non-conforming with the Specifications. The resulting determination of the laboratory will be final and binding on SynCo and Chiron. SynCo will bear the cost of such testing if the testing
demonstrates that the Product is defective or non-conforming and Chiron will bear the cost if the testing demonstrates the Product is neither defective nor non-conforming.

	5.4.
	SynCo
shall indemnify, defend and hold harmless Chiron and its Affiliates from and against any and all losses, claims, damages or liabilities (including but not limited to reasonable
attorney's fees) arising from or relating to (a) any breach by SynCo of its representations, warranties or covenants under this Agreement; or (b) any negligence or intentional wrongdoing
of SynCo or its employees directly related to the cause of such losses, claims, damages or liabilities to the extent 

5

 

any
such losses, claims, damages or liabilities (including but not limited to reasonable attorney's fees) referred to in this Section 5.4 do not arise from an act or omission indemnified by
Chiron pursuant to Section 5.5 hereof; all of the foregoing provided that in the event of defective or non-conforming Product, SynCo shall not be liable or obliged to indemnify,
defend or hold harmless Chiron for any losses, claims, damages or liabilities, whatsoever; in such event, Chiron is only entitled to replacement of the defective or non-conforming Product. 

	5.5.
	Chiron
shall indemnify, defend and hold harmless SynCo, its employees and its Affiliates and employees from and against any and all losses, claims, damages or liabilities (including
but not limited to reasonable attorney's fees), arising from or relating to (a) any use, including in clinical trials, or sale by Chiron, SynCo or any third party of any Product supplied by
SynCo hereunder; (b) any allegation or claim by any third party of infringement of its intellectual property rights by reason of or relating to the manufacture, use or sale of Products by
SynCo, Chiron or any of its Affiliates or any third party; (c) any breach by Chiron of its representations, warranties or covenants under this Agreement; (d) any Material or other
material or information provided by Chiron to SynCo or (e) any negligence or misconduct of Chiron or its employees or its Affiliates or their employees directly related to the cause of such
losses, claims, damages or liabilities (including but not limited to reasonable attorney's fees) to the extent any such losses, claims, damages or liabilities (including but not limited to reasonable
attorney's fees) referred to in this Section 5.5 do not arise from any act or omission indemnified by SynCo pursuant to Section 5.4 hereof.

	5.6.
	Any
person seeking indemnity pursuant to this section (the "Indemnified Party") shall notify the Party from whom indemnification is sought (the "Indemnifying Party") in writing
promptly upon becoming aware of any claim, threatened claim, damage, loss, suit, proceeding or liability ("Claim") to which such indemnification may apply. Failure to provide such notice shall
constitute a waiver of the Indemnifying Party's indemnity obligations hereunder if and to the extent the Indemnifying Party is materially damaged thereby. The Indemnifying Party shall have the right
to assume and control the defence of the Claim at its own expense. If the right to assume and control the defence is exercised, the Indemnified Party shall have the right to participate in, but not
control, such defence at its own expense and the Indemnifying Party's indemnity obligations shall be deemed not to include attorneys' fees and litigation expenses incurred by the Indemnified Party
after the assumption of the defence by the Indemnifying Party. If the Indemnifying Party does not assume the defence of the Claim, the Indemnified Party may defend the Claim; provided, that the
Indemnified Party will not settle or compromise the Claim without consent of the Indemnifying Party, which consent will not be unreasonably withheld. The Indemnified Party shall co-operate
with the Indemnifying Party and will make available to the Indemnifying Party all pertinent information under the control of the Indemnified Party. 

Article 6—Considerations and Payments  

	6.1.
	As
payment in full for Products supplied hereunder or firm binding orders for such Products, Chiron shall pay to SynCo  [***] as set forth in Appendix A.
The prices as set forth in  Appendix A shall be [***], for the first time on  [***] by increasing such
price with [***]. Any and all
prices are to be increased with the [***].

	6.2
	The
Parties recognize and agree that the prices set forth in Appendix A are calculated on the assumption that the Products shall
be manufactured [***].

	6.3
	A
[***] will be payable [***]. SynCo
shall send Chiron an invoice in respect of this amount at least thirty days before such payment is due. 

6

 
	6.4
	SynCo
shall invoice Chiron [***]. Payment shall be made by Chiron within thirty (30) days from receipt
of the relevant invoice. Delivery of the Products shall only take place after payment by Chiron in full of any and all amounts in respect of such Products.

	6.5
	Any
and all amounts to be paid under this Agreement that are not paid at the relevant payment date shall bear interest at a rate of  [***] or part of a month that such amount remains unpaid. Interest shall
be compounded on a  [***].

	6.6
	Upon
the occurrence of an event referred to in Article 8.2(i), any and all amounts then owed under this Agreement, notwithstanding SynCo's right to claim additional damages, if
any, become immediately due and payable.

	6.7
	Neither
Party is entitled to any set-off, recoupment, withholding or any other similar action in respect of any payments to be made under this Agreement. 

Article 7—Confidentiality and Intellectual Property  

        A Party receiving Confidential Information from the other Party or developing Confidential Information hereunder shall not disclose such Confidential Information
to any third party or otherwise for a period extending ten (10) years following expiration or earlier termination of this Agreement, except as follows: 

	(a)
	to
the extent such information is or becomes general public knowledge through no fault of the recipient Party; or

	(b)
	to
the extent such information can be shown by contemporaneous documentation of the recipient Party to have been in its possession prior to receipt thereof hereunder; or

	(c)
	to
the extent such information is received by the recipient Party from a third party without any breach of an obligation to the disclosing Party; or

	(d)
	to
the extent required by law, by local authorities for regulatory purposes or is necessary to perform its obligations under this Agreement, in which case the recipient Party may
disclose the information if the recipient Party gives the other Party prior notice of such disclosure and an opportunity to comment upon the content of the disclosure. However, SynCo shall have the
right, at all times and without the obligation to give notice to Chiron, to use information related to its Plant for its own business purposes and Chiron shall have the right, at all times and without
the obligation to give notice to SynCo, to use the information related to the Products for its own business purposes. 

For
the avoidance of doubt: It is understood that SynCo purchased the Plant and certain related equipment, including computers and other information technology systems, from an Affiliate of Chiron,
and that prior to such purchase the Plant and equipment were utilized by Chiron and/or its Affiliates for the manufacture of Products. It is further understood that certain employees of SynCo formerly
were employees of an Affiliate of Chiron and were engaged directly or indirectly in the manufacture of Products. Notwithstanding anything to the contrary contained herein, and in particularly
notwithstanding paragraph (b) above, all information relating the Specifications, Technology or manufacture of the Products which exists as of the date of this Agreement shall be owned solely
and exclusively by Chiron and shall not be disclosed by SynCo at any time during the term of this Agreement or for a period of ten years following the expiration or earlier termination of this
Agreement, provided that information relating to the manufacture of the Products that is not exclusive to the Products shall not be deemed to be owned by Chiron and the prohibition to disclose such
information shall not apply. 

Each
Party shall use Confidential Information received from the other Party solely for the purposes of this Agreement and for no other purpose whatsoever. 

7

 

Article 8—Term of Agreement  

	8.1
	The
term of this Agreement shall commence as of the Date of Agreement, and will continue until [***], unless
terminated earlier in accordance with this Agreement.

	8.2
	Either
Party may terminate this Agreement prior to [***] (i) if the other Party is declared bankrupt
("failliet"), files for bankruptcy, is adjudged insolvent or files for suspension of payments ("surséance van betaling") or any other similar circumstance under applicable law or
(ii) if the other Party breaches any material obligation of this Agreement and such Party does not fully remedy such default within sixty (60) days after having received a written notice
from the Party asserting the breach.

	8.3
	Chiron
may terminate this Agreement in the event that SynCo, without Chiron's prior written agreement, [***] in
accordance with the terms of this Agreement in any calendar year. This termination right shall be exercisable by Chiron in each case only on or before December 31 of the relevant calendar year.

	8.3
	Article 5.4,
5.5, 5.6, 7,9.2 and 9.6 survive termination of this Agreement. Furthermore, termination of this Agreement will not relieve Chiron of its obligations to pay SynCo
for Products previously supplied hereunder and for commitments which arise directly out of firm purchase orders for Products. 

Article 9—Additional Terms  

	9.1
	Obligations subject to FDA Compliance Agreement. Any and all obligations of each Party under this Agreement are subject to fulfillment
by the other Party of its obligations under the FDA Agreement.

	9.2
	No guarantee SynCo as regards approvals. SynCo does not make and has not made and may not be deemed to make or have made any
representation, warranty or guarantee that approval from the FDA or any other competent regulatory authority will be obtained for Chiron's Menjugate®. The responsibility for obtaining the
approval by the FDA and other competent regulatory authorities, if any, shall solely and exclusively rest on Chiron. This Agreement may not be construed or interpreted so as to transfer to SynCo any
responsibility or part thereof for obtaining such approvals.

	9.3.
	Non-Waiver. Without prejudice to Article 5.6 hereof, the failure by any Party at any time to enforce any of the
terms or provisions or conditions of this Agreement or exercise any right hereunder shall not constitute a waiver of the same or affect the validity of this Agreement or any part hereof, or that
Party's rights thereafter to enforce or exercise the same. No waiver by a Party shall be valid or binding, except if in writing and signed by a duly authorized representative of the waiving Party.

	9.4.
	Severability. In case one or more of the provisions contained in this Agreement shall, for any reason, be held invalid, illegal or
unenforceable in any respect, such holding shall not affect any other provisions of this Agreement, but this Agreement shall be construed by limiting such provision to such extent as would nearly as
possible reflect the intent, purpose and economic effect of such provision, or, if such is not possible, by deleting such provision from this Agreement, provided that the remaining provisions reflect
the intent of the Parties, as evidenced by this Agreement as a whole.

	9.5.
	Captions. All titles and captions in this Agreement are for convenience only and shall not affect its interpretation.

	9.6.
	Law and Arbitration. This Agreement shall be governed, construed and interpreted by the laws of the Netherlands. The Parties agree
that all disputes between them arising out of or relating to this 

8

 

Agreement
shall be settled by arbitration in accordance with the Rules of Conciliation and Arbitration of the International Chamber of Commerce by three arbitrators appointed in accordance with such
Rules. The arbitration proceedings shall take place in Amsterdam, The Netherlands if initiated by Chiron and in Milan, Italy if initiated by SynCo and shall be conducted in the English language.
Judgment on the award may be issued by and enforced by any court of competent jurisdiction. 

	9.7.
	Entire Understanding. This Agreement (including appendices) is the entire understanding and agreement between the Parties relating to
the subject matter hereof and supersedes (except as provided herein) any and all prior arrangements, understandings, and agreements between the Parties whether written or oral relating thereto. For
the sake of completeness, it is acknowledged and agreed that the provisions of that certain contract manufacturing agreement dated July 26, 2001 remain valid for the Products to be manufactured
in the year 2003. No amendments, changes, or modifications of the terms of this Agreement shall be valid or binding unless made in writing and signed by the duly authorized representatives of each
Party.

	9.8.
	Independent Status of Parties. Each Party is an independent party acting in its own name and for its own account. Neither Party has
any authority to act as an agent or representative of the other, or to contract in the name of, or create or assume any obligation against, or otherwise legally bind, the other Party in any way for
any purpose, unless agreed separately in writing. All costs and expenses connected with each Party's activities and performance under this Agreement unless otherwise separately agreed or provided for
in this Agreement are to be borne solely by the Party incurring such costs and expenses.

	9.9.
	No Transfer of Rights or Obligations. Neither of the Parties may transfer any or all of its rights or obligations under this Agreement
to any third party, without the prior written consent of the other Party.

	9.10.
	Press Release. The Parties agree that neither Party shall disclose the existence of or the contents of this Agreement to any third
party without the prior written consent of the other Party.

	9.11.
	Joint and Several Liability. Chiron S.r.l. and Chiron Behring GmbH & Co shall be jointly and severally liable for the
obligations of Chiron under this Agreement. 

        IN
WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed by their duly authorized representatives: 

	 
	 	 

	Chiron S.r.l.:	 	SynCo Bio Partners B.V.:
	

/s/  JOHN LAMBERT      
 John Lambert Dr.
 President, Chiron Vaccines	
 	

/s/  MIC N. HAMERS      
 Mic N. Hamers
 Managing Director
	
Chiron Behring GmbH & Co:	
 	

 
	

/s/  JOHN LAMBERT      
 John Lambert
 President, Chiron Vaccines	
 	

 

9

 
 
 

APPENDIX A
  
    COST OF CERTAIN PRODUCT    
    

        The
[***] of dried purified MenC polysaccharides amounts to  [***]. 

        The  [***] of CRM197 amounts to [***]. 

        These
prices shall be [***], for the first time on  [***], in accordance with Article 6 of the Contract Manufacturing Agreement. 

10

 
 
 

APPENDIX B
  
    LIST OF PRODUCTS    
    

MEN
C polysaccharides

CRM197 

11

 
 
 

APPENDIX C
  
    OPERATING PROCEDURES AND SPECIFICATIONS    
    

MF-MFS-MEC-000
Master Formulation Document MenC polysaccharide 

This document lists all materials, documents, including all BPRs and control methods and equipment for the production of MenC  

MF-MFS-CRM-000
Master Formulation Document for CRM197 

This document lists all materials, documents, including all BPRs and control methods, and equipment for the production of CRM197  

12

 
 
 

APPENDIX D
  
    FIRM ORDERS    
    

Campaign of [***]

  [***]
[***]

Campaign of [***]

  A combined total of [***]  

Campaign of [***]

  A combined total [***]

13

 
 
 

APPENDIX E
  
    QUANTITIES FOR THE YEARS [***]    
    

Campaign of [***]

  A combined total of [***]  

Campaign of [***]

  A combined total of [***]  

Campaign of [***]

  A combined total of [***]  

Campaign of [***]

  A combined total of [***]  

14

 
 
 

APPENDIX F
  
    INTERCOMPANY QUALITY AGREEMENT    
    

        Chiron Vaccines 

Chiron
s.r.l., Siena, Italy and Chiron Behring GmbH & Co., Marburg, Germany

(hereafter called "Chiron") 

	Approved by:	 	 	 	Date: 12. June 2003
	

/s/ Ludger Schwenen	
 	

 	
 	

 
	

Name:    Ludger Schwenen	
 	

 
	

Title:    VP Quality Operations	
 	

 
	

AND
	

Synco Bio-partners B.V.,
	

Amsterdam, The Netherlands

(hereafter called "Synco")
	Approved by:	 	 	 	Date: 20 June 2003
	

/s/ Rob Sprenkels	
 	

 
	

Name:    Rob Sprenkels	
 	

 
	

Title:    Director Quality Affairs	
 	

 

15

	1.
	QUALITY
AGREEMENT 

        1.1   Scope:

        1.1.1 This
agreement defines the Joint Quality Systems between SYNCO and CHIRON for the production and control of the products and activities detailed the Contract
Manufacturing Agreement (to which this document is an appendix). 

        1.1.2 Responsibility
of Quality Assurance, Quality Control and other operational departments for the products and activities detailed in the Contract Manufacturing Agreement
shall be defined by CHIRON and SYNCO as set forth in this document or in standard operating procedures agreed upon by the parties from time to time. 

        1.2   Guiding
Principles: 

        1.2.1 The
responsibilities of the Manufacturer (SYNCO) include production and testing of product in compliance with license requirements, cGMP's and specifications, as set
forth in the provisions that follow. 

        1.2.2 The
Responsibilities of the purchaser (CHIRON) include assuring conformance of product to regulatory requirements for their licensed territory through oversight and
activities, as set forth in the provisions that follow. 

        1.2.3 It
is in both parties' interest to collaborate on overall product performance to assure the consistent quality, integrity, purity and stability of the product. 

        1.2.4 This
agreement shall be incorporated within and constitute a part of the supply agreement between the two companies. 

        1.2.5 In
the event of a conflict between any of the provisions of the Quality Agreement and the Contract Manufacturing Agreement, the provisions of the Contract
Manufacturing Agreement shall govern. 

	2.
	ADMINISTRATIVE
INFORMATION 

        2.1   CHIRON
and SYNCO contact names: See the listing at the end of this agreement. This listing will be reviewed semiannually. 

        2.2   Organizational
Structure 

        2.2.1 Any
significant change in key personnel relevant to the manufacture of the Products at the plant or the respective headquarters involving the Quality department or
quality functions for either parties will be communicated to the other as soon as reasonably possible. 

        2.2.2 Any
change in key personnel relevant to the manufacture of the Products of a critical operation (e.g. production, quality, and validation) of either party will be
communicated to other in writing as soon as reasonably possible. 

        2.2.3 Each
party to maintain information on and communicate to the other party within 1 day identification of debarment of any individuals involved in the manufacture
or control of the product. 

        2.3   Technical
Coordination Meeting. 

        2.3.1 A
Technical Coordination Meeting(TCM) will be established. The meeting will be co-chaired by representatives from both parties. Meeting members to be named
by each company. Permanent members include, site head(s) of Quality, Manufacturing, (other members from QC, Regulatory Affairs, validation and logistics may be included as the need arises). 

        2.3.2 The
TCM will provide oversight for product quality. It will meet on an as required (but normally before the start of each campaign and in the event of issues) and as
agreed to by both parties. The TCM will be the forum to resolve quality matters. This board does not replace the 

 

role
and responsibility of the respective SYNCO or CHIRON Quality Assurance function to disposition product as defined in SOP's. 

        2.3.3 The
TCM will also review such information as, performance, deviations, change control, continuous improvement to be agreed upon by both parties. 

        2.4   Person
in the Plant (PIP) 

        2.4.1 SYNCO
to provide sufficient facilities for CHIRON PIP 

        2.4.2 SYNCO
will allow the CHIRON PIP access to the facility at any time reasonably requested, during manufacturing and testing operations for product for the purposes of
observing various operations, assisting in any problem solving, facilitating additional tasks and communicating issues to others at CHIRON. Upon mutual agreementas circumstances require, additional
CHIRON personnel to be provided access to manufacturing and testing operations as part of a collaborative effort as required to accomplish the specific function, i.e., investigations. The PIP will
facilitate these requests and coordination with SYNCO. 

	3.
	DURATION
OF AGREEMENT 

        3.1   The
Quality Agreement will be reviewed as necessary to ensure that the roles and responsibilities reflect current practice. This agreement can be modified as needed with
the written approval of both parties. The Contract Manufacturing Agreement will not be updated as changes occur, as these changes will be governed by the change control system and subsequent
documentation updates. 

        3.2   This
Quality Agreement will effective upon and will expire with the termination of the supply agreement except for circumstances set forth in the agreement. 

	4.
	MANUFACTURING
AND LOGISTICS 

        4.1   General

        4.1.1 The
definition of "cGMP" shall mean the regulatory requirements for current good manufacturing practices promulgated by the FDA under the FD&C Act 21 C.F.R. 210 et
seq. and under the PHS Act 21 C.F.R. 600-610, and the applicable regulatory guidance documents and current industry practice promulgated by the European Committee and the Canadian Health
Protection Branch as the case may be, as the same may be amended from time to time. 

        4.1.2 SYNCO
agrees not to subcontract any of the manufacturing, testing, release and/or handling of the product unless prior written agreement has been obtained from CHIRON.
Refer to Change Management, section 9. 

        4.2   Premises 

        4.2.1 The
premises and equipment used to manufacture the product will be maintained according to current regulatory requirements and in accordance with the controlled
documentation. 

        4.2.2 Manufacturing
of the product will be conducted in a suitably controlled environment and such facilities will be regularly monitored for parameters critical to the
process to demonstrate compliance with cGMP regulations and guidelines and any conditions registered in the Biologics License Application (BLA) and other global manufacturing authorizations. 

        4.2.3 .
SYNCO will ensure that CHIRON proprietary information and documentation will be controlled in order to maintain confidentiality obligations. 

        4.3   Raw
Materials, Cell Bank and Product Samples 

        4.3.1 Raw
materials used in the manufacturing or testing of the product must be approved and tested in accordance with documents jointly reviewed and approved by CHIRON and
SYNCO. 

2

 

        4.3.2 SYNCO
will implement appropriate system to maintain certification of raw materials, in process materials, chemicals and excipients used in the manufacture of product.
Synco shall assure each lot is in full compliance with the approved specifications. 

        4.3.3 Materials
procured by SYNCO 

        4.3.3.1 SYNCO
will procure all materials for use in the product from mutually approved vendors and in full compliance with the specifications and SOPs mutually agreed upon
by SYNCO and CHIRON 

        4.3.3.2 CHIRON
and SYNCO will jointly approve all vendors or suppliers of critical raw materials, reagents, or components used in the manufacture and testing as well as all
contract testing of product (collectively, "Third Party Vendors"). The procedures relating to documentation of approval are to follow procedure described in Section 6.1 and any vendor or
supplier changes are to follow change control procedures described in Section 9. 

        4.3.3.3 SYNCO
is responsible for ensuring that all materials are received, stored, segregated and used correctly, and all materials are appropriately tested upon receipt and
are released prior to use. SYNCO is also responsible for holding the relevant Certificate of Analysis, Certificate of Compliance and/or certification of origin (as appropriate) for the materials. 

        4.3.3.4 SYNCO
is responsible for ensuring appropriate separation and/or segregation of any materials that may present potential hazard to the materials used in the product
and/or the production of the product. 

        4.3.4 Materials
Provided by CHIRON for SYNCO 

        4.3.4.1 CHIRON
is responsible for ensuring that any materials or components provided by CHIRON for use in the product are in full compliance with the specifications
registered. CHIRON will provide SYNCO with relevant information on storage conditions and holdtimes. 

        4.3.4.2 CHIRON
will provide SYNCO the necessary information for SYNCO to receive and disposition any raw material or component supplied by CHIRON prior to or with a
scheduled receipt. 

        4.3.4.3 SYNCO
is responsible for receiving and appropriately storing the working seeds and providing sufficient and suitable storage facility. SYNCO will notify CHIRON if
there is a deviation associated with the working seed shipping, receipt or testing. Refer to Deviation section 7.3. SYNCO will use reasonable effort that during storage, deterioration,
interference, theft, product contamination, or mixture with any other materials shall take place. 

        4.4   Product
and Lot Numbers 

        SYNCO
will assign a unique part number and or lot number to each media or solution, in-process intermediate and product lot produced. The SYNCO part and lot numbers are
recorded on each batch record. The numbering procedures will allow for unique, traceable identifiers, which are compatible with CHIRON and SynCo inventory management systems. 

        4.5   Manufacturing
and Equipment Data 

        4.5.1 SYNCO
is responsible for keeping records of equipment usage, cleaning, testing, pressure holds, etc. and any maintenance/calibration performed. 

        4.5.2 SYNCO
will provide CHIRON with access to manufacturing equipment data relevant to the manufacture and testing of the PRODUCTS upon request. 

        4.6   Storage
and Shipment of THE PRODUCTS 

3

 

        4.6.1 SYNCO
will provide sufficient and suitable storage facilities that meet the storage specifications for the product as documented and agreed upon in either batch
records or SOPs. 

        4.6.2 The
product will be suitably packaged for transit as detailed and agreed in an agreed SOP. CHIRON and SYNCO will collaborate in the logistics of performing shipping
validation(s) and the ongoing use of temperature monitors. 

        4.6.3 SYNCO
Quality will assure that only released material meeting mutually agreed predefined requirements is shipped for further processing. 

	5.
	QUALITY
CONTROL 

        5.1   General

        5.1.1 The
testing activities for the product that are to be performed by SYNCO will be documented in jointly approved SYNCO specifications. SYNCO is responsible for
performing validated, cGMP testing. CHIRON will provide validated test methodology. 

        5.1.2 Testing
on SYNCO manufactured product, or intermediates will be performed in accordance with product specifications and SOPs that have been jointly approved by CHIRON
and SYNCO. In addition, any decision to implement any new analytical methods or testing with respect to the product will in each case be a decision and mutual agreement of both parties as outlined by
Change Management (Section 9). 

        5.2   In-Process
and product Testing 

        5.2.1 SYNCO
will perform testing of in-process intermediates and of the PRODUCTS using specifications and methods of analysis that have been mutually approved by
SYNCO and CHIRON. Routine samples required for both companies test requirements will be identified in the batch records and/or SOPs. 

        5.3   QC
Reporting Results 

        5.3.1 SYNCO's
Quality Assurance will sign the Certificates of Analysis confirming that the product has been tested, results have been reviewed and approved from a relational
and technical perspective and meet the requirements of the product specifications. 

        5.4   Retention
Samples 

        5.4.1 SYNCO
will store a quantity of THE PRODUCTS as retention samples. The amount of retention samples will be agreed upon. CHIRON may also retain samples at its own
discretion. 

        5.5   Out-of-Specification
(OOS) Investigations: 

        5.5.1 SYNCO
is responsible for investigating any testing performed by SYNCO that produces a result that fails to meet a specification. Each investigation will follow SYNCO
procedures and the procedures recommended by regulatory agencies. See section 6.3. 

        5.5.2 SYNCO
will notify CHIRON as soon as reasonably possible of any confirmed test result that is out of specification; for OOS which may impact material already released,
SYNCO to notify CHIRON within 24 hours. These test results will be handled per section 6.3. 

	6.
	QUALITY
ASSURANCE 

        6.1   Documentation

        6.1.1 Product
Specific Master Batch Records and SOPs 

        6.1.1.1 SYNCO
is responsible for creating the product specific manufacturing and testing master documentation. 

4

 

        6.1.1.2 CHIRON
and SYNCO will jointly approve each document version of product specific raw materials and product specifications, master batch records and test method SOPs
prior to its use in manufacturing or testing. 

        6.1.1.3 Changes
to previously approved documents will be handled as outlined by Change Management (see section 9). 

        6.1.2 General
SOPs: SYNCO is responsible for creating and maintaining all SOPs and other documentation at SYNCO required to support cGMP operations at SYNCO. CHIRON will be
allowed to review such SOPs either on site or upon request. 

        6.2   Deviations
and Investigations 

        6.2.1 Any
deviation from the process and SOPs during manufacture, storage or testing must be appropriately explained, investigated, documented, and approved in the batch
records or analytical records. The deviation documentation must identify the cause and the corrective action, where appropriate, and must assess product impact with respect to product quality. 

        6.2.2 SYNCO
will communicate to CHIRON any batch or batch related component that contains a major process or testing deviation or confirmed OOS where the deviation has the
likely potential to impact product quality as soon as reasonably possible.. SYNCO will also communicate as soon as reasonably possible to CHIRON any significant facility or product trend investigation
that has the potential to impact product quality or product supply. 

        6.2.2.1 Where
CHIRON performs testing, CHIRON is responsible to notify SYNCO of any batch or associated batch of product that contains a major process or testing deviation
or confirmed OOS where the deviation has the likely potential to impact product safety, efficacy or quality as soon as reasonably possible. 

        6.2.3 Some
deviations, confirmed OOS and/or failures may require that additional testing, stability, or validation be conducted. This work will be performed as agreed upon
in writing by all the parties. SYNCO will not perform such additional testing on any batch of product without prior written approval from the CHIRON Quality. Testing performed according to SOPs in
order to confirm an OOS does not require CHIRON prior approval. 

        6.2.4 Where
a major investigation is open greater than 30 days from initiation, SYNCO Quality will provide to CHIRON Quality an interim report on day 31 and regularly
there after until closure of the investigation. For all others, tracking and reporting will be done in accordance with site SOP's. 

        6.2.5 Both
companies will notify one another within 24 hours of discovery if any problems are discovered that may impact product batch(s) previously released and/or
shipped. 

        6.3   Disposition
of Product (Batch Release or Rejection) 

        6.3.1 SYNCO
Manufacturer's Release 

        6.3.1.1 Manufacturer's
Release: SYNCO's QualityAssurance, upon acceptable review and completeness of the batch documentation of operations performed by SYNCO, will release
the batch for shipping to Chiron. 

        6.3.2 License
Holder's Product Release, where the license holder is the CHIRON. 

        6.3.2.1 CHIRON
Quality is responsible for the regulatory release of the THE PRODUCTS according to CHIRON internal procedures following review of the SYNCO documentation.
CHIRON will forward a copy of THE PRODUCT final release notices to SYNCO. 

5

 

        6.3.3 Product
Release Issues 

        6.3.3.1 THE
PRODUCTS—Any problem discovered prior to release by CHIRON or SYNCO that may be likely to cause rejection or hold of the product will be communicated
to the other party as soon as reasonably possible. Any subsequent rejection by CHIRON shall occur within 60 days from CHIRONs review of the SYNCO manufacturing documentation unless another time
frame is mutually agreed upon. 

        6.3.3.2 In
the case of latent defects (defects not evident at the time of release), SYNCO and CHIRON will communicate regarding any such defect and any possible rejection
will occur within 30 days from discovery unless another time frame is mutually agreed upon. SYNCO and CHIRON will work collaboratively to achieve a resolution. 

        6.3.3.3 When
the product release issue is discovered by SYNCO and the SYNCO rejects the lot, then the lot is rejected. CHIRON cannot release a lot that SYNCO has rejected. 

        6.3.3.4 When
CHIRON identifies a product disposition issue a joint investigation would be conducted, the product disposition would be mutually determined at the conclusion
of that investigation. Also refer to section 8.3 Non-Conformity Dispute Resolution. 

        6.3.4 Batch
Rejection 

        6.3.4.1 SYNCO
may terminate the processing of an in process intermediate without prior notification to CHIRON. SYNCO will notify CHIRON of any batch or portion of batch of
Product being considered for rejection by SYNCO. If CHIRON finds a batch or portion of a of Product unacceptable, CHIRON will reject and forward a copy of the rejection notice to SYNCO, stating the
reason to reject the lot(s). 

        6.4   Records
Retention 

        6.4.1 SYNCO
will retain all of its manufacturing batch records and all referenced documents, production procedures, testing records and methods and shipping records of
product in accordance with SYNCO record retention requirements and CFR 211.180d and for not less than 10 years. 

        6.4.2 At
least 30 days prior to record destruction, SYNCO will notify CHIRON in writing. CHIRON may request that batch records and associated documentation be
forwarded to CHIRON for archiving. 

	7.
	REGULATORY
COMPLIANCE 

        7.1   Regulatory
Documentation 

        7.1.1 Regulatory
Affairs from CHIRON will assess regulatory strategy and plans for filings or other regulatory correspondence or requests. 

        7.1.2 CHIRON
is responsible for ensuring all appropriate regulatory filings and export documentation is filed with, and approved by, Regulatory Agencies prior to shipment. 

        7.1.3 The
CHIRON and SYNCO technical coordination meeting (TCM) will act as the point of contact with Regulatory Affairs regarding issues that impact the registration
information for the product. CHIRON will be responsible for assigning regulatory categories for change notifications with consultation with SYNCO. 

        7.1.4 SYNCO
will provide CHIRON in a timely manner with a copy of any SYNCO manufacturing and control records for product or materials which are required for any regulatory
filings. Such records will be in SYNCO standard formats unless otherwise agreed upon by CHIRON and SYNCO. 

6

 

        7.1.5 SYNCO
will provide CHIRON with all documents reasonably requested relating to any FDA or other regulatory authority pre-approval inspection of the SYNCO
Facility for CHIRON product or processes. SYNCO will work collaboratively with CHIRON on reaching resolution to any questions, pre-approval or post-approval commitments. 

        7.1.6 CHIRON
shall review relevant sections of regulatory submissions with SYNCO prior to their submission. CHIRON shall provide a copy of relevant sections of final
regulatory submissions to SYNCO for reference during inspections. 

        7.1.7 For
Annual Report generation, refer to Section 11.2. 

        7.1.8 As
required, SYNCO will maintain a Site Master File or equivalent for their facility and allow CHIRON reference to such documents upon request. 

        7.2   Regulatory
Inspections and Correspondence 

        7.2.1 SYNCO
will notify CHIRON of any product specific regulatory inspections that may involve the product and permit a representative from CHIRON to be present, if
requested by CHIRON. The role of the representative would be defined and mutually agreed upon. 

        7.2.2 Agreement
should be reached between CHIRON and SYNCO prior to making any commitment to any regulatory agency regarding the product. 

        7.2.3 Each
party will promptly notify and provide copies of any regulatory correspondence directly relating to manufacturing activities by SYNCO along with any other
documentation received or prepared on the product to the other party as soon a reasonably possible after receipt. 

        7.2.4 Each
Party will notify the other Party in a timely manner of any meetings or substantive discussions with the FDA, EMEA, or any other regulatory authority that
directly relate to the manufacture of THE PRODUCTS, supply and/or control of the product, and that the other Party will have the right to but not the obligation to have at least one representative
participate in such meetings or discussions. 

        7.3   Right
to Audit 

        7.3.1 SYNCO
will permit CHIRON at reasonable intervals and with reasonable prior notice to SYNCO and during SYNCO's normal business hours to review and audit at the SYNCO
Facility, provided manufacture and /or testing of the PRODUCTS is ongoing. Such reviews and audits will include any systems, original batch records and other primary documents and any areas of the
SYNCO Facility and any other laboratory and warehousing facilities used by or on behalf of SYNCO in the manufacture, testing, storage, or shipping of product, product samples or receiving any material
or component used in performing the Services. 

        7.3.2 SYNCO
will permit CHIRON to conduct preparatory audits forpre-approval inspections (PAI). 

        7.3.3 SYNCO
acknowledges that the CHIRON audit team may include consultants employed by CHIRON to audit on CHIRON behalf. While at the SYNCO facility, CHIRON personnel will
comply with all applicable SYNCO policies, procedures and regulations. 

        7.3.4 The
CHIRON Corporate audit to perform at least one standard cGMP compliance audit per year to encompass all cGMP operations. SYNCO and CHIRON will work to have
reasonable expectations concerning duration and audit team size. 

        7.3.5 SYNCO
will permit CHIRON Quality Unit to conduct event reviews, in addition to annual audits, to address significant product quality, performance or safety problems.
These events 

7

 

should
be requested, scheduled and conducted at the first available date. Event reviews may result from but are not limited to the following: 

        7.3.5.1 A
Warning Letter or other regulatory actions from FDA, EMEA, or other regulatory agency relating to the manufacture, testing, storage, or shipment of THE PRODUCTS by
SYNCO 

        7.3.5.2 Rejection
of in-process intermediates or THE PRODUCTS 

        7.3.5.3 Repeated
product complaints. 

        7.3.5.4 Unusual
data trends with respect to the manufacturing, testing, storage, or shipment of product, including, but not limited to a series of batch failures or
stability failures. 

        7.4   Audit
Closeout 

        7.4.1 An
exit meeting will be held with representatives from CHIRON and SYNCO to discuss significant audit observations. 

        7.4.2 CHIRON
will provide a written report of all observations within 30 days to SYNCO. Within 30 days of the audit report receipt, SYNCO will provide a
written response to all findings that details corrective action to be implemented. SYNCO will follow up to ensure that all corrective actions are implemented and provide a report to CHIRON upon
implementation Where corrective action will require extended period to implement regular reports on progress will be provided to the CHIRON by the SYNCO. Frequency will be mutually agreed upon. 

	8.
	DISPUTE
RESOLUTION 

        8.1   Licensing
or Regulatory Filing Strategy Dispute 

        8.1.1 In
the event that a dispute arises between CHIRON and SYNCO with regard to regulatory strategy, the TCM shall in good faith promptly attempt to reach an agreement. 

        8.2   Test
Result Dispute 

        8.2.1 In
the event that a testing result dispute arises between CHIRON and SYNCO in the testing performed for the product, the resolution will proceed in stages. 

        8.2.1.1 The
first stage requires direct communication between QC Management from both parties to identify the appropriate contacts, who will then determine that the methods
of analysis are the same and are being executed in the same manner at both sites. 

        8.2.1.2 Second,
if the investigation dictates, carefully controlled and split samples should be sent from one site to another in an attempt to reach agreement. 

        8.2.1.3 Should
there be a failure to achieve resolution, analysts from both parties may be required to work side by side through the analysis of a mutually agreeable sample. 

        8.2.1.4 If
these actions fail to achieve resolution the issue would go to the TCM for resolution 

        8.3   Product
Batch Non-Conformity Dispute 

        8.3.1 In
the event that a dispute arises between CHIRON and SYNCO in the non-conformity of a batch of the product, the Quality representatives from both
companies shall in good faith promptly attempt to reach an agreement. If agreement is not reached, the issue will be taken to the TCM for resolution. 

        8.4   Final
disposition of product batch and final disposition is the responsibility of the CHIRON Quality Assurance function as defined in procedures. 

8

 
	9.
	CHANGE
MANAGEMENT 

        9.1   Procedures
for Change Control 

        9.1.1 There
will be change control procedures at SYNCO that are mutually agreed upon by both parties. 

        9.1.2 All
changes go through a technical and cGMP impact assessment. SYNCO will notify CHIRON in advance of any planned changes by SYNCO possibly affecting the regulatory
submission and/or available supply of the product. This includes any changes to validated facilities, utilities, computer systems, equipment or processes. 

        9.1.3 SYNCO
will have responsibility for providing justification for the changes and validating any such changes to cGMP standards jointly agreed to. 

        9.1.4 Change
control procedures will include a requirement for SYNCO to obtain written approval from CHIRON prior to the implementation of any change possibly affecting the
regulatory submission and/or available supply of the product. 

        9.2   Scope

        9.2.1 The
scope of the change management process includes product manufacturing, testing, storage and shipping processes. The associated changes may relate to: the master
batch records (e.g. master formulas), bill of materials, analytical standards, test methods (for raw materials and product), raw material and product specifications; and any changes to validated
facilities, utilities, computer systems, equipment or processes used in the cleaning, manufacturing, testing, storage or shipment with respect to THE PRODUCTS. 

        9.3   Specification
Changes 

        9.3.1 If
a specification change is required for the in-process intermediates, or THE PRODUCTS the requesting party will advise the other party in writing. As
appropriate, both parties will cooperate in good faith to implement the changes to the specification and or impacted activities/processes as soon as possible, or as required by regulatory authorities.
Prior to implementing a specification change, both parties will give due consideration and negotiate in good faith in an attempt to reach agreement on any financial or scheduling impacts of such
specification change. 

        9.4   Document
Distribution 

        9.4.1 CHIRON
shall be on the distribution list for SYNCO's documents specific to the product as described above and in section 6 Likewise, SYNCO shall be on CHIRON's
distribution list for appropriate specifications. 

	10.
	PRODUCT
AND PROCESS VALIDATION 

        10.1 Process 

        10.1.1 SYNCO
is responsible for validating the manufacturing process, Chiron is responsible for ensuring that the manufacturing process at SYNCO is validated. 

        10.1.2 SYNCO
will maintain cGMP validation status of facilities and process equipments with respect to the manufacturing, storage, shipping and cleaning procedures that are
used in the services provided by SYNCO 

        10.1.3 SYNCO
will work collaboratively with CHIRON to validate the product shipping process. 

9

 

        10.2 Cleaning
Validation 

        10.2.1 SYNCO
is responsible for ensuring that cleaning processes are validated for all products produced in the SYNCO facilities and that adequate cleaning is carried out on
components and equipment between batches to prevent contamination at SYNCO. Chiron is responsible for the validation of the cleaning processes related to Chiron's products. 

        10.2.2 CHIRON
and SYNCO will cooperate to establish cleaning limits for the facilities involved in the manufacture of product. 

        10.2.3 The
cleaning procedures and analytical methodology will be jointly reviewed. SYNCO and CHIRON will review cleaning procedures and testing methodology pertaining to
product. 

        10.3 Equipment,
Computer, Facility, and Utilities Qualification 

        10.3.1 SYNCO
is responsible for all equipment, computer, facility, and utility qualification activities associated with the product at SYNCO 

        10.3.2 CHIRON
has responsibility to review and approve validation master plans. CHIRON has the right to review protocols and final reports as they relate to product
manufactured for the CHIRON at the SYNCO site and mutually agreed upon. 

        10.3.3 SYNCO
will maintain cGMP validation status on the SYNCO Facility, as well as the utilities, computers and equipment associated with the product and will make
validation reports available to CHIRON for review. 

        10.3.4 SYNCO
to develop procedures and implementation plans to assure all critical computer systems and software compliance with FDA requirements. 

        10.4 Laboratory
Qualification and Validation 

        10.4.1 SYNCO
is responsible for ensuring that all laboratories are in compliance with cGMP and are qualified in all of the methodology associated with the product and
facility. SYNCO will maintain
cGMP validation status on the methods used to test the product. SYNCO will provide any existing analytical documentation to assist in methods transfer or methods validation. 

	11.
	CAMPAIGN
REVIEW and ANNUAL REPORT 

        11.1 Campaign
Review 

        11.1.1 SYNCO
will perform an Campaign Review, Timing to align with the Annual Report or other regulatory agency requirements. SYNCO will share Campaign review reports. 

        11.1.2 This
report will cover all manufacturing, testing, and storage activities performed by SYNCO. It will contain a review of any changes at SYNCO, in the manufacturing,
testing, storage or validation of the product in the previous review period and will be formally connected to the change control system. Additionally it will include major deviations with deviation
trending and a summary of batches made, released, and rejected. Also, control charting or trend analysis of key product parameters or performance criteria will be performed as agreed to in advance by
the parties. Any abnormalities will be explained in the campaign Review. 

        11.1.3 CHIRON
and SYNCO will agree on format and content of the report and all Parties will make all reasonable efforts to meet to discuss information in the Campaign
Review(s). 

10

 

        11.2 Annual
Report 

        11.2.1 CHIRON
is responsible for preparing any Annual Report as required by applicable regulations, including 21 CFR 314.7(g)(3), 314.81(b)(2), and/or 601.12(d), (f)(3). 

        11.2.2 CHIRON
and SYNCO will agree on format and content of the information and all Parties will make all reasonable efforts to meet to discuss information for inclusion in
the Annual Report preferably at the same time as Annual Product Review discussion. 

 
 

List of Contacts    
    

	CHIRON: Lead Quality	 	SYNCO: Lead Quality
	Name: Pietro Bagnato	 	Name: Rob Sprenkels
	Title: Head QA, External Manufacturing	 	Title: Director Quality Affairs
	Work:++39 0577 242262	 	Work: +31 (0)20 7503631
	email: Pietro_Bagnato@chiron.it	 	Email: Rob_Sprenkels@synco-biopartners.com
	Fax::+39 0577 2436	 	Fax: +31 (0)20 7503601
	

CHIRON: Lead Operations	
 	

SYNCO: Lead Operations
	Name: Russell Thirsk	 	Name: Eust Clemens
	Title: Head of External Manufacturing	 	Title: Director Operations
	Work:++39 0577 243610	 	Work: +31 (0)20 7503675
	email: Russell_Thirsk@chiron.it	 	Email: Eust_Clemens@synco-biopartners.com
	Fax::+39 0577 243674	 	Fax:: +31 (0)20 7503601

 
 

[***] CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN
  OMITTED AND FILED SEPARATELY WITH THE COMMISSION.
  CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH
  RESPECT TO THE OMITTED PORTIONS.    
    

11

QuickLinks

Exhibit 10.212

[***]  CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS. CONTRACT MANUFACTURING
AGREEMENT

APPENDIX A COST OF CERTAIN PRODUCT

APPENDIX B LIST OF PRODUCTS

APPENDIX C OPERATING PROCEDURES AND SPECIFICATIONS

APPENDIX D FIRM ORDERS

APPENDIX E QUANTITIES FOR THE YEARS [***]

APPENDIX F INTERCOMPANY QUALITY AGREEMENT

List of Contacts

[***]  CERTAIN INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND FILED SEPARATELY WITH THE COMMISSION. CONFIDENTIAL TREATMENT HAS BEEN REQUESTED WITH RESPECT TO THE OMITTED PORTIONS.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00054-of-00352.parquet"}]]